Document:

exv4w4

 

EXHIBIT
4.4

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, OR
TRANSFERRED UNTIL: (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR SUCH APPLICABLE STATE
SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO; OR (ii) IN THE OPINION OF COUNSEL
REASONABLY ACCEPTABLE TO THE COMPANY, REGISTRATION UNDER THE SECURITIES ACT OR SUCH APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED OFFER, SALE OR TRANSFER.

IOMAI CORPORATION

Stock Purchase Warrant

     THIS WARRANT is issued in connection with the closing of the private placement of IOMAI
CORPORATION, a Delaware corporation (the “Company”), of its Series C Preferred Stock, par value
$0.01 per share (the “Series C Preferred Stock”) effective this 4th day of December, 2002, by the
Company to FRIEDMAN BILLINGS RAMSEY & CO., INC. or any subsequent assignee or transferee
(hereinafter referred to collectively as the “Holder” or “Holders”).

          1. Issuance of Warrant. The Company hereby grants to the Holder the right to purchase
two hundred fifty thousand (250,000) shares of Series C Preferred Stock upon the surrender hereof,
at the Exercise Price (as defined in Section 3 below). The shares of Series C Preferred
Stock issuable upon exercise of this Warrant are hereinafter referred to as the “Warrant Shares.”

          2. Term. Subject to the terms and conditions set forth herein, this Warrant shall be
immediately exercisable in whole or in part at any time and from time to time from the date hereof
(the “Exercise Date”) until 5:00 p.m. eastern time on December 4, 2007 (the “Expiration Date”) and
shall be void thereafter, provided that the provisions of Section 6 hereof shall survive in
accordance with their terms.

          3. Price. The purchase price per share for which the Warrant Shares may be purchased
pursuant to the terms of this Warrant shall be $.4421 per share (the “Exercise Price”) as adjusted
from time to time pursuant to Section 8 hereof.

          4. Exercise.

               (a) At the sole discretion of the Holder, this Warrant may be exercised by the Holder hereof
from the Exercise Date until the Expiration Date as to part or all of the Warrant Shares. The
Holder may exercise the Warrant by surrender of this Warrant and the Notice of Exercise attached
hereto as Exhibit A, duly completed and executed on behalf of the Holder, at the office of
the Company, 20 Firstfield Road, Suite

 

 

250, Gaithersburg, MD 20878, or at such other address as the Company shall designate in a
written notice to the Holder hereof, together with a certified check payable to the Company for the
aggregate Exercise Price of the shares of Series C Preferred Stock so purchased.

               (b) In lieu of paying the exercise price pursuant to Section 4(a) above, the Holder
may exercise the Warrant via cashless exercise by converting the Warrant, in whole or in part (the
“Conversion Right”), into Warrant Shares. To exercise the Conversion Right, the Holder shall
surrender to the Company this Warrant and the Notice of Exercise attached hereto, duly completed
and executed by the Holder to evidence the exercise of the Conversion Right. Upon exercise of the
Conversion Right, the Company shall deliver to the Holder a certificate(s) representing that number
of Warrant Shares which is equal to the quotient obtained by dividing (x) the value of the
portion of the Warrant being converted at the date the Conversion Right is exercised (determined by
subtracting (A) the aggregate Exercise Price relating to the portion of the Warrant being converted
calculated immediately prior to the exercise of the Conversion Right from (B) the aggregate fair
market value of the portion of the Warrant being converted (determined on the basis of the fair
market value per share of that number of Warrant Shares purchasable upon exercise of such portion
of the Warrant immediately prior to the exercise of the Conversion Right)), by (y) the fair
market value per share of one share of Series C Preferred Stock on the date of exercise of the
Conversion Right. For purposes of this calculation, the fair market value per share of Series C
Preferred Stock shall be: (i) if a public market for the Series C Preferred Stock exists at the
time of such exercise, the average of (A) the closing bid and asked prices of the Series C
Preferred Stock quoted in the Over-The-Counter Market Summary or (B) the last reported sale price
of the Series C Preferred Stock or the closing price quoted on the Nasdaq National Market or on any
exchange on which the Series C Preferred Stock is listed, whichever is applicable, as published in
The Wall Street Journal for the five (5) trading days prior to the date of determination of fair
market value; or (ii) if there is no public market for the Series C Preferred Stock, determined by
the Company’s Board of Directors in good faith. Any references in this Warrant to the “exercise”
of any Warrants, and the use of the term “exercise” herein, shall be deemed to include (without
limitation) any exercise of the Conversion Right.

               (c) Upon exercise of this Warrant as aforesaid, the person entitled to receive the Warrant
Shares issuable upon such exercise shall be treated for all purposes as the holder of record of
such shares as of the close of business on the date of exercise. As promptly as practicable on or
after such date, and in any event within ten (10) days thereafter, the Company shall execute and
deliver to the Holder of this Warrant a certificate or certificates for the total number of whole
Warrant Shares for which this Warrant is being exercised (net of any Warrant Shares applied upon
exercise of the Conversion Right), in such names and denominations as are requested by such Holder.
If this Warrant shall be exercised with respect to less than all of the Warrant Shares, the
Company, at its expense, will issue to the Holder a new Warrant covering the number of Warrant
shares with respect to which this Warrant shall not have been exercised, which new Warrant shall be
identical to this Warrant except for the number of shares and date of issuance. If upon exercise
of this Warrant, the Holder would be entitled to acquire a

-2-

 

fractional share of the Series C Preferred Stock, such fractional share shall be disregarded,
and the number of shares subject to this Warrant shall be rounded down to the next lower number of
shares, and the Holder shall be entitled to receive from the Company a cash payment equal to the
product of the per share Exercise Price multiplied by such fraction. The Company covenants and
agrees that it will pay when due any and all state and federal issue taxes which may be payable in
respect of the issuance of this Warrant or the issuance of any Warrant Shares upon exercise of this
Warrant.

          5. Covenants and Conditions. The above provisions are subject to the following:

               (a) Neither this Warrant nor the Warrant Shares have been registered under the Securities Act
or any state securities laws (“Blue Sky Laws”). This Warrant has been acquired for investment
purposes and not with a view to distribution or resale and may not be pledged, hypothecated, sold,
made subject to a security interest, or otherwise transferred without: (i) an effective
registration statement for such Warrant under the Securities Act and such applicable Blue Sky Laws;
or (ii) an opinion of counsel reasonably satisfactory to the Company that registration is not
required under the Securities Act or under any applicable Blue Sky Laws. Transfer of the Warrant
Shares issued upon the exercise of this Warrant shall be restricted in the same manner and to the
same extent as the Warrant, and the certificates representing such Warrant Shares shall bear
substantially the following legend:

THE SHARES OF SERIES C PREFERRED STOCK REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF l933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAW
AND MAY NOT BE TRANSFERRED UNTIL: (i) A REGISTRATION STATEMENT UNDER THE ACT OR SUCH APPLICABLE
STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO; OR (ii) IN THE OPINION OF
COUNSEL REASONABLY ACCEPTABLE TO THE COMPANY, REGISTRATION UNDER THE ACT OR SUCH APPLICABLE STATE
SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER.

                 The Holder and the Company agree to execute such other documents and instruments as counsel to
the Company reasonably deems necessary to effect the compliance of the issuance of this Warrant and
any shares of Series C Preferred Stock issued upon exercise hereof with applicable federal and
state securities laws, including compliance with applicable exemptions from the registration
requirements of such laws. The Holder shall, as a condition to the issuance of any Warrant Shares,
become a party to that certain Stockholders’ Agreement dated as of December 4, 2002 among the
Company and the signatories thereto, as the same may be amended from time to time.

               (b) The Company covenants and agrees that all Warrant Shares which may be issued upon exercise
of this Warrant will, upon issuance and payment therefor, be legally and validly issued and
outstanding, fully paid and nonassessable. The

-3-

 

Company shall at all times reserve and keep available for issuance upon the exercise of this
Warrant such number of authorized but unissued shares of Series C Preferred Stock as will be
sufficient to permit the exercise in full of this Warrant.

          6. Registration Rights. The shares of the Company’s common stock, par value $.01 per
share issuable upon conversion of the Series C Preferred Stock issuable upon exercise of this
Warrant are entitled to and subject to the conditions applicable to the registration rights as set
forth in that certain Investor Rights Agreement dated as of November ___, 2002 among the Company
and the signatories thereto, as the same may be amended from time to time.

          7. Transfer of Warrant. Subject to the provisions of Section 5, this Warrant
may be transferred by presentation of the Warrant to the Company with written instructions for such
transfer and by the execution by such transferee of an investment letter in a form reasonably
satisfactory to the Company: (a) by operation of law or by reason of the reorganization of the
Company; or (b) to affiliates and employees of Friedman Billings Ramsey & Co., Inc. who are subject
to the same restrictions on transferability under this Section 7. Upon such presentation
for transfer and receipt of such investment letter, the Company shall promptly execute and deliver
a new Warrant or Warrants in the form hereof in the name of the assignee or assignees and in the
denominations specified in such instructions. The Company shall pay all expenses in connection
with the preparation, issuance and delivery of Warrants under this Section 7.
Notwithstanding anything to the contrary herein, any transfer of any portion of this Warrant to a
competitor of the Company shall require the prior written consent of the Company. For purposes of
foregoing, a competitor of the Company means any person or entity that is engaged in the research,
development, manufacturing, licensing, marketing or distribution of pharmaceuticals, drug delivery
products or drug delivery technologies.

          8. Adjustment Upon Changes in the Company Series C Preferred Stock.

               (a) If all or any portion of this Warrant shall be exercised subsequent to any stock split,
stock dividend, recapitalization, combination of shares of the Company, or other similar event,
occurring after the date hereof, then the Holder exercising this Warrant shall receive, for the
aggregate price paid upon such exercise, the aggregate number and class of shares which such Holder
would have received if this Warrant had been exercised immediately prior to the record date for
such stock split, stock dividend, recapitalization, combination of shares, or other similar event.
If any adjustment under this Section 8(a) would create a fractional share of Series C
Preferred Stock or a right to acquire a fractional share of Series C Preferred Stock, such
fractional share shall be disregarded and the number of shares subject to this Warrant shall be the
next higher number of shares, rounding all fractions upward. Whenever there shall be an adjustment
pursuant to this Section 8(a), the Company shall promptly notify the Holder or Holders of
this Warrant of such adjustment, setting forth in reasonable detail the event requiring the
adjustment and the method by which such adjustment will be calculated.

               (b) If all or any portion of this Warrant shall be exercised subsequent to any merger,
consolidation, exchange of shares, separation, reorganization

 

 

or liquidation of the Company, or other similar event, occurring after the date hereof, as a
result of which shares of Series C Preferred Stock shall be changed into the same or a different
number of shares of the same or another class or classes of securities of the Company or another
entity, or the holders of Series C Preferred Stock are entitled to receive cash or other property,
then the Holder exercising this Warrant shall receive, for the aggregate price paid upon such
exercise, the aggregate number and class of shares, cash or other property which such Holder would
have received if this Warrant had been exercised immediately prior to such merger, consolidation,
exchange of shares, separation, reorganization or liquidation, or other similar event. If any
adjustment under this Section 8(b) would create a fractional share of Series C Preferred
Stock or a right to acquire a fractional share of Series C Preferred Stock, such fractional share
shall be disregarded and the number of shares subject to this Warrant shall be the next higher
number of shares, rounding all fractions upward. Whenever there shall be an adjustment pursuant to
this Section 8(b), the Company shall promptly notify the Holder or Holders of this Warrant
of such adjustment, setting forth in reasonable detail the event requiring the adjustment and the
method by which such adjustment was calculated.

          9. Notice of Certain Events. In case:

               (a) The Company shall take a record of the holders of its Series C Preferred Stock for the
purpose of entitling them to receive any dividend or other distribution, or any right to subscribe
for or purchase any shares of capital stock of any class, or to receive any other rights; or

               (b) Of any capital reorganization, any reclassification of shares of capital stock of the
Company (other than a subdivision or combination of outstanding shares of Series C Preferred Stock
to which Section 8 applies), or any consolidation or merger of the Company or the sale or
transfer of all or substantially all of the assets of the Company; or

               (c) Of any voluntary dissolution, liquidation, or winding up of the Company;

then the Company shall mail (at least twenty (20) days prior to the applicable date referred to in
subclause (x) or in subclause (y) below, as the case may be), to the Holder at the
address set forth in the Company’s stock records, a notice stating: (x) the date on which a record
is to be taken for the purpose of such dividend, distribution, or rights, or, if a record is not to
be taken, the date as of which the holders of Series C Preferred Stock of record to be entitled to
such dividend, distribution, or rights are to be determined; or (y) the date on which such
reclassification, capital reorganization, consolidation, merger, sale, transfer, dissolution,
liquidation, or winding up is expected to become effective, and, if applicable, the date as of
which it is expected that holders of Series C Preferred Stock of record shall be entitled to
exchange their shares of Series C Preferred Stock for securities or other property deliverable upon
such reclassification, capital reorganization, consolidation, merger, sale, transfer, dissolution,
liquidation, or winding up.

-5-

 

               10. Miscellaneous. This Warrant shall be governed by the laws of the State of
Delaware without giving effect to choice of law provisions that might require the application of
any other law. The headings in this Warrant are for purposes of convenience and reference only,
and shall not be deemed to constitute a part hereof. Neither this Warrant nor any term hereof may
be changed or waived orally, but only by an instrument in writing signed by the Company and the
Holder of this Warrant. This Warrant shall be binding upon and inure to the benefit of each of the
Company and the Holder hereof and their respective heirs, successors and assigns, except that the
Company shall not have the right to delegate its obligations hereunder or to assign its rights
hereunder or any interest herein, except as otherwise provided herein.

[Signature Page Follows]

-6-

 

     IN WITNESS WHEREOF, Iomai Corporation has caused this Warrant to be executed by its duly
authorized officer to be effective as of the date first written above.

	 	 	 	 	 
	 	 	IOMAI CORPORATION
	 
	 	 	 	 
	 

	 	By:	 	/s/ Stanley C. Erck 
	 

	 	 	 	 
	 

	 	Name:	 	Stanley C. Erck 
	 

	 	 	 	 
	 

	 	Title:	 	Chief Executive Officer and President 
	 

	 	 	 	 

Accepted and Agreed to as of

the Date First Written Above:

	 	 	 	 	 	 	 
	FRIEDMAN BILLINGS RAMSEY & CO., INC.	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 

	 	 

	 	 	 	 
	Name:
	 	 	 	 	 	 
	 

	 	 

	 	 	 	 
	Title:
	 	 	 	 	 	 
	 

	 	 

	 	 	 	 

 

 

EXHIBIT A

NOTICE OF EXERCISE

TO: Iomai Corporation

     The undersigned, the Holder of the foregoing Warrant and pursuant to the terms hereof, hereby
elects to exercise rights represented by said Warrant for, and to purchase thereunder, shares of
the Company’s Series C Preferred Stock covered by said Warrant, and tenders herewith payment of the
purchase price in full for such shares of $___, by:

	 	 	 	 	 
	                    

	 	(a)
	 	cash, through the delivery of a certified or official bank check; or
	 
	 	 	 	 
	                    

	 	(b)
	 	exercising the Conversion Right provided under Section 4(b) of the Warrant by the surrender of said Warrant.

     The undersigned hereby requests that certificates for such shares (or any other securities or
other property issuable upon such exercise) be issued in the name of and delivered to the
undersigned at the address set forth below.

	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	 	 	Name
	 
	 	 	 	 	 	 
	Date:

	 	 	 	 	 	 
	 

	 	 
	 	 	 	 
	 

	 	 	 	 	 	Signature
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	Address:exv4w5

 

EXHIBIT
4.5

INVESTOR RIGHTS AGREEMENT

BY AND AMONG

IOMAI CORPORATION

AND

THE PURCHASERS LISTED ON EXHIBIT A HERETO

December 4, 2002

 

 

IOMAI CORPORATION INVESTOR RIGHTS AGREEMENT

     This INVESTOR RIGHTS AGREEMENT (this “Agreement”), dated as of December 4, 2002 is
entered into by and among Iomai Corporation, a Delaware corporation (the “Company”), and
the individuals and entities listed on Exhibit A hereto (collectively, the
“Purchasers”).

RECITALS:

     WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Company,
Elan International Services, Ltd. (“EIS”) Elan Pharmaceutical Investments, Ltd (“EPIL
I”) and certain other parties are entering into a Restructuring Agreement of even date herewith
(the “Restructuring Agreement”) whereby EIS is receiving shares of the Company’s Series B
Preferred Stock, US$0.01 par value per share (the “Series B Preferred”) in exchange for
certain property including, without limitation, 4,776 common shares of Xairo Corporation, Ltd., a
Bermuda Subsidiary of the Company (“Xairo”).

     WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Company and
certain Purchasers are entering into a Series C Preferred Stock Purchase Agreement of even date
herewith (the “Purchase Agreement”) whereby, among other things, such Purchasers are
purchasing certain shares of the Company’s Series C Preferred Stock, US$0.01 par value per share
(the “Series C Preferred”).

     WHEREAS, the Company and EPIL I (by transfer of rights from EIS) are parties to a certain
Registration Rights Agreement dated as of October 21, 1998 (the “Old Registration Rights
Agreement”).

     WHEREAS, the Company and EPIL I have agreed to terminate the Old Registration Rights Agreement
and enter into this Agreement.

     WHEREAS, the. Company and the Purchasers desire to provide for certain arrangements with
respect to (i) the registration of shares of capital stock of the Company under the Securities Act
(as defined below); (ii) the Purchasers’ right of first refusal with respect to certain issuances
of securities of the Company, and (iii) certain covenants of the Company.

     NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this
Agreement and other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the parties hereto agree as follows:

SECTION 1

CERTAIN DEFINITIONS

     1.1 Definitions. As used in this Agreement, the following terms shall have the
following respective meanings:

     “Affiliate” means, as to any specified Person, any other Person directly or indirectly
controlling or controlled by or under the direct or indirect common control with such specified
Person; provided, however, that none of the Purchasers will be deemed an Affiliate
of the

 

 

Company for the purposes of this Agreement. For the purposes of this definition, “control”
(including, with correlative meanings, the terms “controlled by” and “under common control with”)
means the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of the Person, whether through the ownership of voting securities or by
agreement or otherwise. Any Person owning voting securities of another Person which constitute
over 10% of the voting control of the Person will be deemed an Affiliate under this definition.

     “Available Undersubscription Amount” means the difference between the total of all
Basic Amounts available for purchase by Purchasers pursuant to Section 3 and the Basic Amounts
subscribed for pursuant to Section 3.

     “Basic Amount” means, with respect to a Purchaser, his, her or its pro rata portion of
the Offered Securities determined by dividing the aggregate number of shares of Common Stock then
held by such Purchaser (giving effect to the conversion or exercise into Common Stock of all
convertible or exercisable securities then held by such Purchaser) by the total number of shares of
Common Stock then held by all Purchasers (giving effect to the conversion or exercise into Common
Stock of all convertible or exercisable securities then outstanding).

     “Certificate of Incorporation” shall mean the Company’s Second Amended and Restated
Certificate of Incorporation, as in effect on the date of this Agreement and as may be amended from
time to time.

     “Code” means the Internal Revenue Code of 1986, as amended.

     “Commission” means the Securities and Exchange Commission, or any other Federal agency
at the time administering the Securities Act.

     “Common Stock” means the common stock, $0.01 par value per share, of the Company.

     “Company” has the meaning ascribed to it in the introductory paragraph hereto.

     “Company Sale” means (a) a merger or consolidation in which (i) the Company is a
constituent party, or (ii) a Subsidiary is a constituent party and the Company issues shares of its
capital stock pursuant to such merger or consolidation, except any such merger or consolidation
involving the Company or a Subsidiary in which the holders of capital stock of the Company
immediately prior to such merger or consolidation continue to hold immediately following such
merger or consolidation more than 50% by voting power of the capital stock of or ownership interest
in (A) the surviving or resulting entity or (B) if the surviving or resulting entity is a wholly
owned subsidiary of another entity immediately following such merger or consolidation, the parent
entity of such surviving or resulting entity; (b) the sale, in a single transaction or. series of
related transactions, (i) by the Company of all or substantially all the assets of the Company
(except where such sale is to a wholly owned Subsidiary of the Company) or (ii) by the stockholders
of the Company of more than 50% by voting power of the then-outstanding capital stock of the
Company to a single purchaser, or (c) the lease or license on an exclusive basis, in a single
transaction or series of related transactions, of all or substantially all of the intellectual
property of the Company (except where such lease or license is to a wholly owned Subsidiary of the
Company).

-2-

 

     “Competitor” means any Person involved in the research, development, manufacturing,
licensing, marketing or distribution of drug delivery products or drug delivery technologies.

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any successor
statute, and the rules and regulations of the Commission issued under such Act, as they each may,
from time to time, be in effect.

     “Indemnified Party” means a party entitled to indemnification pursuant to Section 2.6.

     “Indemnifying Party” means a party obligated to provide indemnification pursuant to
Section 2.6.

     “Initiating Holder” means any Purchaser initiating a request for registration pursuant
to Section 2.1 (a) or 2.1(b), as the case may be.

     “Initial Public Offering” means the initial underwritten public offering of shares of
Common Stock pursuant to an effective Registration Statement.

     “Market Price” means the average of the daily closing prices per share of the
Company’s Common Stock for the 30 consecutive trading days immediately preceding the day that the
Series B Registration Notice was sent. The closing price for each day shall be the last sale price
regular way or, in case no such sale takes place on such day, the average of the closing bid and
asked prices regular way, in either case on the principal national securities exchange on which the
shares are listed or admitted to trading, or if the shares are not so listed or admitted to
trading, on The NASDAQ Stock Market or, if prices for the shares are not quoted on The NASDAQ Stock
Market, the average of the highest reported bid and lowest reported asked prices as furnished by
the National Association of Securities Dealers, Inc. through NASDAQ or through a similar
organization if NASDAQ is no longer reporting such information.

     “Notice of Acceptance” means a written notice from a Purchaser to the Company
containing the information specified in Section 3.1(b).

     “Offer” means a written notice of any proposed or intended issuance, sale or exchange
of Offered Securities containing the information specified in Section 3.1(a).

     “Offered Securities” means (i) any shares of Common Stock, (ii) any other equity
securities of the Company, including, without limitation, shares of preferred stock, (iii) any
option, warrant or other right to subscribe for, purchase or otherwise acquire any equity
securities of the Company or (iv) any debt securities convertible into capital stock of the
Company.

     “Other Holders” means the holders of securities of the Company set forth on Exhibit B
hereto who are entitled, as of the date hereof, by contract with the Company, to have the
securities set forth on Exhibit B hereto included in a Registration Statement.

     “Person” means an individual or an entity, including a corporation, share company,
limited liability company, partnership, trust, association, governmental body or any other body
with legal personality separate from its equityholders or members.

-3-

 

     “Proceeding” means any action, arbitration, examination, investigation, hearing,
litigation, or suit (whether civil, criminal, administrative, judicial or investigative, whether
formal or informal and whether public or private) commenced, brought, conducted or heard by or
before, or otherwise involving, any governmental body or arbitrator of competent jurisdiction.

     “Prospectus” means the prospectus included in any Registration Statement, as amended
or supplemented by an amendment or prospectus supplement, including post-effective amendments, and
all material incorporated by reference or deemed to be incorporated by reference in such
Prospectus.

     “Purchase Agreement” has the meaning ascribed to it in the recitals hereto.

     “Purchaser” has the meaning ascribed to it in the introductory, paragraph hereto and
shall include any person or entity deemed a “Purchaser” pursuant to Section 5.

     “Qualified IPO” means a firm commitment Initial Public Offering resulting in at least
$25,000,000 of gross proceeds to the Company, and pursuant to which the Company obtains a listing
for its shares on the New York Stock Exchange or the Nasdaq National Market System.

     “Refused Securities” means those Offered Securities as to which a Notice of Acceptance
has not been given by the Purchasers pursuant to Section 3.1.

     “Register,” “registered” and “registration” refer to a registration
effected by preparing and filing a Registration Statement in compliance with the Securities Act,
and the declaration or ordering of the effectiveness of such Registration Statement.

     “Registrable Shares” means (a) the shares of Common Stock issued or issuable upon
conversion of the Shares and (b) any other shares of Common Stock held by any Purchaser; provided,
however, that shares of Common Stock which are Registrable Shares shall ease to be Registrable
Shares upon their sale pursuant to a Registration Statement or Rule 144 under the Securities Act.
Wherever reference is made in this Agreement to a request or consent of holders of a certain
percentage of Registrable Shares, the determination of such percentage shall include shares of
Common Stock issuable upon conversion of the Shares even if such conversion has not yet been
effected.

     “Registration Expenses” means all expenses incurred by the Company in complying with
the provisions of Section 2, including, without limitation, all registration and filing fees,
exchange listing fees, rating agency fees, printing expenses, messenger and delivery expenses, fees
and expenses of counsel for the Company, state Blue Sky fees and expenses (if applicable), and the
expense of any special audits incident to or required by any such registration, and the reasonable
fees and expenses of one counsel selected by the Selling Stockholders holding a majority of the
Registrable Shares to be including in the Registration Statement, but excluding underwriting
discounts and selling commissions.

     “Registration Statement” means a registration statement filed by the Company with the
Commission for a public offering and sale of securities of the Company (other than a registration
statement on Form S-8 or Form S-4, or their successors, or any other form for a similar limited

-4-

 

purpose, or any registration statement covering only securities proposed to be issued in
exchange for securities or assets of another corporation).

     “Representatives” of a specified Person are such Person’s (current or former) limited
partners, general partners, shareholders, members, directors, managers, officers, employees,
consultants, advisors, agents and attorneys.

     “Restructuring Agreement” has the meaning ascribed to it in the recitals hereto.

     “Securities Act” means the Securities Act of 1933, as amended, or any successor
Federal statute, and the rules and regulations of the Commission issued under such Act, as they
each may, from time to time, be in effect.

     “Selling Stockholder” means any Purchaser and his, her or its successors or assigns
owning Registrable Shares included in a Registration Statement.

     “Series B Preferred” means the Company’s Series B Preferred Stock, $0.01 par value per
share.

     “Series C Preferred” means the Company’s Series C Preferred Stock, $0.01 par value per
share.

     “Series B Registrable Shares” means Registrable Shares issued or issuable upon
conversion of Series B Preferred or any other shares of Common Stock issued in respect of such
shares; provided, that such shares shall not be deemed Series B Registrable Shares if held
by a Competitor.

     “Shares” means (i) the shares of Series B Preferred issued to certain Purchasers
pursuant to the terms of the Restructuring Agreement, (ii) the shares of Series C Preferred issued
to certain Purchasers pursuant to the Purchase Agreement and (iii) any shares of Common Stock held
by the Purchasers following conversion of shares of Series B Preferred or Series C Preferred.

     “Stockholders’ Agreement” means the Stockholders’ Agreement dated as of the date
hereof by and among the Company, the stockholders listed on Exhibit A thereto and the Purchasers
listed on Exhibit B thereto.

     “Subsidiary” or “Subsidiaries” means any corporation, partnership, trust,
limited liability company or other Person (i) in which the Company directly or indirectly through
one or more of its subsidiaries. holds stock or other ownership interests representing (a) more
than 50% of the voting power of all outstanding stock or ownership interests of such entity or (b)
the right to receive more than 50% of the net assets of such entity available for distribution to
the holders of outstanding stock or ownership interests upon a liquidation or dissolution of such
entity, or (ii) with respect to which the Company directly or indirectly through one or more of its
subsidiaries has the right, pursuant to agreement or otherwise, to appoint 50% or more of the
members of the board of directors (or similar governing body).

-5-

 

     “Undersubscription Amount” means, with respect to a Purchaser, any additional portion
of the Offered Securities attributable to the Basic Amounts of other Purchasers as such Purchaser
indicates it will purchase or acquire should the other Purchasers subscribe for less than their
Basic Amounts.

SECTION 2

REGISTRATION RIGHTS

     2.1 Required Registrations.

          (a) At any time after six months following the closing of the Initial Public Offering, a
holder or holders of

               (i) Registrable Shares holding in the aggregate at least 25% of the Registrable Shares then
outstanding may request, in writing, that the Company effect the registration of all or part of
their Registrable Shares; provided, that the sale of the Registrable Shares proposed to be
registered is reasonably expected to result in gross proceeds of at least $5,000,000; and

               (ii) Series B Registrable Shares holding in the aggregate at least 51% of the Series B
Registrable Shares then outstanding may request, in writing, that the Company effect the
registration of all or part of their Series B Registrable Shares; provided, that (1) the
sale of the Series B Registrable Shares proposed to be registered is reasonably expected to result
in gross proceeds of at least $5,000,000, (2) such holder(s) of Series B Registrable Shares first
offer such Series B Registrable Shares to the other Purchasers pursuant to the terms of Section
2.1(a)(ii)(A) below, and (3) such Series B Registrable Shares to be registered constitute, in the
aggregate and on an as-converted basis, a number of shares equal to 100/0 or less, of the Company’s
shares then listed on the. New York Stock Exchange or through the Nasdaq National Market System.

                    (A) If holder(s) of Series B Registrable Shares wish to request the registration of their
Series B Registrable Shares in accordance with Section 2:1(a)(ii), such holder(s) shall deliver a
written notice (a “Series B Registration Notice”) to the Purchasers disclosing the number
of Series B Registrable Shares to be so registered. For 30 days following their receipt of the
Series B Registration Notice, the Purchasers shall have the option to- elect to purchase such
Series B Registrable Shares at the Market Price. Each Purchaser desiring to purchase any of the
Series B Registrable Shares shall give written notice of such desire, specifying the number of
Series B Registrable Shares such Purchaser desires to purchase (the “Acceptance Notice”) to
such holder(s) within such 30-day period. If the aggregate number of Series B Registrable Shares
subscribed for in Acceptance Notices is fewer than 90% of the number of Series B Registrable Shares
set forth in the Series B Registration Notice, the Purchasers’ rights pursuant to this Section
2.1(a)(ii)(A) shall lapse in their entirety and be of no further effect (and no purchase hereunder
shall take place). If the aggregate number of Series B Registrable Shares subscribed for in
Acceptance Notices is between 90% and 100% of the number of Series B Registrable Shares set forth
in the Series B Registration Notice, the available Series B Registrable Shares shall be allocated
in the proportions desired to be purchased as set

-6-

 

forth in the Acceptance Notices. If the aggregate number of Series B Registrable Shares
subscribed for in Acceptance Notices exceeds the number of Series B Registrable Shares set forth in
the Series B Registration Notice, the available Series B Registrable Shares shall be allocated
amongst the participating Purchasers pro rata, in the proportion that the number of shares of
Common Stock Equivalents held by each such Purchaser bears to the number of shares of Common Stock
Equivalents held by all such participating Purchasers (or in such other proportion as such
Purchasers mutually agree). The purchase and sale of the Series B Registrable Shares pursuant to
this Section 2.1(a)(ii)(A) shall be made at the Market Price, and shall take place at the offices
of the Company at 10 a.m. local time on the 45th day following the date of the Acceptance Notice
(or on such other date agreed upon by the applicable holder(s) of Series B Registrable Shares and
the participating Purchasers).

                    (B) Any purchase and sale of Series B Registrable Shares pursuant to Section 2.1(a)(ii)(A)
shall, for purposes of Section 2.1(e), be deemed to constitute the one registration required of the
Company pursuant to Section 2.1(a)(ii).

                    (C) The rights of a Purchaser to purchase Series B Registrable Shares, pursuant to Section
2.1(a)(ii)(A) shall lapse in their entirety and be of no further effect if such Purchaser, after
having delivered an Acceptance Notice, fails to consummate the purchase of Series B Registrable
Shares in accordance with Section 2.1(a)(ii)(A).

          (b) At any time when the Company is eligible to file a Registration Statement on Form S-3 (or
any successor form relating to secondary offerings), a Purchaser or Purchasers holding Registrable
Shares may request, in writing, that the Company effect the registration on Form S-3 (or such
successor form), of Registrable Shares having an aggregate value of at least $2,000,000 (based on
the current public market price on the date of such request).

          (c) Upon receipt of any request for registration pursuant to Section 2.1(a) or (b), the
Company shall promptly give written notice of such proposed registration to all other Purchasers in
accordance with Section 6.1. Such Purchasers shall have the right, by giving written notice to the
Company within 30 days after the Company provides its registration notice, to request to have
included in such registration the number of Registrable Shares as such Purchasers may request in
such notice of election, subject in the case of an underwritten offering to the terms of Section
2.1(d). Thereupon, the Company shall, as expeditiously as possible, use its best efforts to effect
the registration on an appropriate registration form of all Registrable Shares that the Company has
been requested to so register; provided, however, that in the case of a
registration requested under Section 2.1(b), the Company will only be obligated to effect such
registration on Form S-3 (or any successor form).

          (d) If the Initiating Holders intend to distribute the Registrable Shares covered by their
request by means of an underwriting, they shall so advise the Company as a part of their request
made pursuant to Section 2.1 (a) or (b), as the case may be, and the Company shall include such
information in its written notice referred to in Section 2.1(c) (if applicable). In such event (i)
the right of any other Purchaser to include its Registrable Shares shall be conditioned upon such
other Purchaser’s participation in such underwriting on the terms set forth herein, and (ii) all
Purchasers including Registrable Shares in such registration shall enter into an underwriting, sale
or similar agreement upon customary terms with the underwriter or

-7-

 

underwriters managing the offering. The Initiating Holders shall have the right to select the
managing underwriter(s) for any underwritten offering requested pursuant to Section 2.1 (a) or (b),
subject to the approval of the Company, which approval will not be unreasonably withheld. If any
Purchaser who has requested inclusion of its Registrable Shares in such registration as provided
above disapproves of the terms of the underwriting, such person may elect, by written notice to the
Company, to withdraw its Registrable Shares from such Registration Statement and underwriting. In
any underwritten offering initiated:

               (i) pursuant to Section 2.1(a)(i) or (b), if the managing underwriter advises the Company that
marketing factors require a limitation on the number of shares to be underwritten, then the number
of Registrable Shares to be included in the Registration Statement and underwriting shall be
decreased accordingly, and such limitation of shares shall be allocated among all Purchasers
requesting registration in proportion, as nearly as practicable, to the respective number of
Registrable Shares held by them on the date of the request for registration made by the Initiating
Holders pursuant to Section 2.1(a)(i) or (b), as the case may be. If any Purchaser would thus be
entitled to include more Registrable Shares than such Purchaser requested to be registered, the
excess shall be allocated among other requesting Purchasers pro rata in the manner described in the
preceding sentence.

               (ii) pursuant to Section 2.1(a)(ii), if the managing underwriter advises the Company that
marketing factors require a limitation on the number of shares to be underwritten, then the number
of Registrable Shares to be included in the Registration Statement and underwriting shall be
decreased accordingly, and the Company shall include Registrable Shares in the Registration
Statement (up to the aggregate of such reduced amount) in the following priority: (A) first, the
Series B Registrable Shares requested to be registered, in proportion, as nearly as practicable, to
the respective number of Series B Registrable Shares held by the participants on the date of the
request for registration, and (B) second, any other Registrable Shares requested to be registered,
in proportion, as nearly as practicable, to the respective number of Registrable Shares held by the
participants on the date of the request for registration. If any Purchaser would thus be entitled
to include more Registrable. Shares than such Purchaser requested to be registered, the excess
shall be allocated among other requesting Purchasers pro rata in the manner described in the
preceding sentence.

The rights pursuant to Section 2.1 shall be exerciseable in priority to the rights of all Other
Holders to incidental (or “piggyback’) registration rights; provided, that, to the extent
required pursuant to any existing agreement between the Company and an Other Holder (and only to
such extent), the rights of the Purchasers to include Registrable Shares in a registration pursuant
to Section 2.1 (c) shall be exercisable on a pro rata basis among such Other Holder(s) and the
Purchasers participating in such registration on the basis of the number of shares owned by such
Other Holder(s) and such Purchasers.

          (e) The Company shall not be required to effect (i) more than two registrations pursuant to
Section 2.1(a)(i), (ii) more than one registration pursuant to Section 2.1(a)(ii), or (iii) more
than two registrations pursuant to Section 2.1 (b) in any twelve month period. For purposes of
this Section 2.1(e), a Registration Statement shall not be counted (A) until such time as such
Registration Statement has been declared effective by the Commission (unless the Initiating Holders
withdraw their request for such registration) and the Company has

-8-

 

complied in all material respects with its obligations under this Agreement with respect
thereto, (B) if, after the Registration Statement has become effective, the offering or sale of
Registrable Shares pursuant thereto is or becomes the subject of any stop order, injunction or
other order or requirement of the Commission or any other governmental body, securities exchange or
self-regulatory body, or if any court or other governmental body, securities exchange or
self-regulatory body otherwise limits such offer or sale (unless and until such limitation ceases
to exist and at least 90% of the Registrable Shares included in the registration have been sold),
(C) if the Registration Statement does not remain effective for the periods set forth in Section
2.4(a)(i), or (D) in the case of a registration pursuant to Section 2.1(a), until the Purchasers
are allowed to sell at least 90% of the Registrable Shares included in the registration.

          (f) If at the time of any request to register Registrable Shares pursuant to this Section 2.1,
the Company is engaged or has plans to engage in a registered underwritten public offering or is
planning to engage in a financing, acquisition, merger, asset sale or similar transaction which, in
the good faith determination of the Company’s Board of Directors, would be materially and adversely
affected by the requested registration, then the Company may at its option direct that such request
be delayed for a period of not more than 120 days from the effective date of such request,
provided, that the Company shall thereafter use its best efforts to cause such Registration
Statement to become effective as soon as practical after filing; provided, further,
that such right to delay a request shall be exercised by the Company not more than once in any 12
month period.

     2.2 Incidental Registration.

          (a) Whenever the Company proposes to file a Registration Statement (other than pursuant to
Section 2.1 or in connection with its Initial Public Offering) at any time and from time to time,
it will, not less than 15 days nor more than 30 days, prior to the reasonably anticipated date of
such filing, give written notice to all Purchasers of its intention to do so. Upon the written
request of a Purchaser or Purchasers given within 15 days after the Company provides such notice
(which request shall state the intended method of disposition of such Registrable Shares), the
Company shall, subject to Section 2.2(b), cause all Registrable Shares which the Company has been
requested by such Purchaser or Purchasers to register to be registered under the Securities Act to
the extent necessary to permit their sale or other disposition in accordance with the intended
methods of distribution specified in the request of such Purchaser or Purchasers; provided,
that the Purchasers, if requested by the Company, have provided the Company the information
required from them for such registration; provided, further, that the Company shall
have the right to postpone or withdraw any registration effected pursuant to this Section 2.2
without obligation to any Purchaser. If required pursuant to the terms of existing agreements
between the Company and Other Holders, these rights may be exercisable only on a pro rata basis
with Other Holders on the basis of the number of shares owned by Other Holders and the Purchasers
exercising their rights to incidental (or “piggyback”) registration for the same registration.

          (b) If the registration for which the Company gives notice pursuant to Section 2.2(a) is a
registered public offering involving an underwriting, the Company shall so advise the Purchasers as
a part of its written notice made pursuant to Section 2.2(a). In such event, (i) the right of any
Purchaser to include his, her or its Registrable Shares in such registration pursuant to

-9-

 

Section 2.2 shall be conditioned upon such other Purchaser’s participation in such
underwriting on the terms set forth herein, and (ii) all Purchasers including Registrable Shares in
such registration shall enter into an underwriting agreement upon customary terms with the
underwriter or underwriters selected for the underwriting by the Company. If any Purchaser who has
requested inclusion of his, her or its Registrable Shares in such registration as provided above
disapproves of the terms of the underwriting, such person may elect, by written notice to the
Company, to withdraw his, her or its Registrable Shares from such Registration Statement and
underwriting. If the managing underwriter advises the Company that marketing; factors require a
limitation on the number of shares to be underwritten, the shares held by holders other than the
Purchasers and Other Holders shall be excluded from such Registration Statement and underwriting to
the extent deemed advisable by the managing underwriter, and, if further reduction of the number of
shares is required, the number of shares that may be included in the Registration Statement and
underwriting shall be allocated among all Purchasers and Other Holders requesting registration in
proportion, as nearly as practicable, to the respective number of shares of Common Stock (on an
as-converted basis) held by them on the date the Company gives the notice specified in Section
2.2(a). If any Purchaser or Other Holder would thus be entitled to include more shares than such
holder requested to be registered, the excess shall be allocated among other requesting Purchasers
and Other Holders pro rata in the manner described in the preceding sentence.

     2.3 Aggregation. For any Purchaser that is a partnership, corporation or limited
liability company, the general partner, limited partners, retired partners, shareholders, members,
retired members and Affiliates of such Purchaser, or the members or retired members of the
foregoing, as applicable, or the estates, beneficiaries and family members of any such general
partner, limited partners, retired partners, shareholders, members, and retired members and any
trusts for the benefit of any of the foregoing persons shall be deemed to be a single “Purchaser,”
and any pro rata reduction pursuant to Section 2.1 (c) or 2.2(b) with respect to such Purchaser
shall be based upon the aggregate amount of Registrable Shares owned by all entities and
individuals included in such “Purchaser,” as defined in this sentence.

     2.4 Registration Procedures.

          (a) If and whenever the Company is required by Section 2 to effect the registration of any
Registrable Shares under the Securities Act, the Company will, as expeditiously as possible:

               (i) prepare and file with the Commission a Registration Statement with respect to such
Registrable Shares and use its best efforts to cause that Registration Statement to become
effective as soon as practicable, and to keep the Registration Statement effective for at least six
months from the effective date (subject to extension for the amount of time offers and sales may be
suspended as a result of any stop order, injunction or other order or requirement of any
governmental body, securities exchange or self-regulatory body); provided, that (A) the
Company may keep the Registration Statement effective for a lesser period if all such Registrable
Shares have been sold thereunder and (B) if the Registration Statement relates to an underwritten
offering, the Company shall, if requested in writing by counsel for the underwriters, keep the
Registration Statement effective for such longer period as in the written

-10-

 

opinion of such counsel for the underwriters a Prospectus is required by law to be delivered
in connection with sales of Registrable Shares included therein by an underwriter or dealer;

               (ii) prepare and file with the Commission any amendments and supplements to the Registration
Statement and the Prospectus included in the Registration Statement as may be necessary to comply
with the provisions of the Securities Act;

               (iii) before filing any Registration Statement, Prospectus or amendments or supplements to any
Registration Statement or Prospectus, provide copies of all documents proposed to be filed to one
counsel selected by the holders of a majority of the Registrable Shares participating in the
registration;

               (iv) furnish to each Selling Stockholder such reasonable numbers of copies of the Registration
Statement, the Prospectus, each amendment and supplement to the Registration Statement or the
Prospectus, and any other documents as such Selling Stockholder may reasonably request in order to
facilitate the public sale or other disposition of the Registrable Shares owned by such Selling
Stockholder,

               (v) use reasonable efforts to register or qualify the Registrable Shares covered by the
Registration Statement under the securities or blue sky laws of such states as the Selling
Stockholders shall reasonably request, and do any and all other acts and things that may be
necessary or desirable to enable the Selling Stockholders to consummate the public sale or other
disposition in such states of the Registrable Shares owned by the Selling Stockholder;
provided, however, that the Company shall not be required in connection with this
subsection (v) to qualify as a foreign corporation or execute or file a general consent to service
of process in any jurisdiction, unless the Company is already subject to service in such
jurisdiction and except as may be required by the Securities Act;

               (vi) cause all such Registrable Shares to be listed on each securities exchange or automated
quotation system on which similar securities issued by the Company are then listed;

               (vii) promptly make available for inspection by the Selling Stockholders, any managing
underwriter participating in any disposition pursuant to such Registration Statement, and any
attorney or accountant or other agent retained by any such underwriter or selected by the Selling
Stockholders, all financial and other records, pertinent corporate documents and properties of the
Company and cause the Company’s officers, directors, employees and independent accountants to
supply all information reasonably requested by an such seller, underwriter, attorney, accountant or
agent in connection with such Registration Statement;

               (viii) provide a transfer agent and registrar for all such Registrable Shares not later than
the effective date of such Registration Statement;

               (ix) in the event of the issuance of any stop order suspending the effectiveness of a
Registration Statement, or of any order suspending or preventing the use of any related Prospectus
or suspending the qualification of any Common Stock included in such

-11-

 

Registration Statement for sale in any jurisdiction, use its best efforts to obtain promptly
the withdrawal of such stop order,

               (x) promptly notify one counsel selected by holders of a majority of the Registrable Shares
and the managing underwriter or underwriters, if any, and confirm any such oral notification in
writing promptly thereafter:

          (1) when the Registration Statement, the Prospectus or any Prospectus supplement
related thereto or post-effective amendment to the Registration Statement has been filed,
and, with respect to the Registration Statement or any post-effective amendment thereto,
when the same has become effective;

          (2) of any request by the Commission for amendments or supplements to the Registration
Statement or the Prospectus or for additional information;

          (3) of the issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement or, upon becoming aware, the initiation of any proceedings by any
Person for that purpose; and

          (4) of the receipt by the Company of any notification with respect to the suspension of
the qualification of any Registrable Shares for sale under the securities or Blue Sky laws
of any jurisdiction or, upon becoming aware, the initiation or threat of any proceeding for
such purpose.

               (xi) enter into and perform its obligations under such customary agreements (including, in the
case of an underwritten offering, -underwriting agreements in usual and customary form, with the
managing underwriter(s) of such offering) and take all such other customary actions as the
underwriters reasonably request in order to expedite or facilitate the disposition of such
Registrable Shares;

               (xii) provide a CUSIP number for all Registrable Shares not later than the effective date of
the Registration Statement; and

               (xiii) make available to its security holders, as soon as reasonably practicable, an earnings
statement satisfying the provisions of Section 11(a) of the Securities Act and Rule 158 thereunder
covering the period of at least twelve months beginning with the first day of the Company’s first
full calendar quarter after the effective date of the Registration Statement.

          (b) If the Company has delivered a Prospectus to the Selling Stockholders and after having
done so the Prospectus is amended to comply with the requirements of the Securities Act, the
Company shall promptly notify the Selling Stockholders and, if requested, the Selling Stockholders
shall immediately cease making offers and sales of Registrable Shares and return all Prospectuses
to the Company. The Company shall promptly provide the Selling Stockholders with revised
Prospectuses and, following receipt o£ the revised Prospectuses, the Selling Stockholders may be
free to resume making offers and sales of the Registrable Shares.

-12-

 

          (c) Whenever a Registration Statement covering Registrable Shares pursuant to any section of
this Agreement is effective and the Company determines that, based upon advice of counsel, such
registration statement requires amendment or supplementing, the Company shall notify all Purchasers
whose Registrable Shares are included in such Registration Statement of such fact and shall
promptly cause such Registration Statement to be amended or supplemented, as the case may be, and
shall notify all such Purchasers when such amendment or supplement has been filed and, as to any
such amendment, declared effective. Purchasers shall not sell any Registrable Shares until such
latter notice is provided. In addition, if such Registrable Shares were not to be sold by means of
an underwriting, the Company shall be entitled to delay the filing of such amendment or supplement
for a period not to exceed 60 days if the Board of Directors determines in good faith that such
amendment or supplement would have a material adverse effect on an existing proposal or plan by the
Company to engage in a financing, acquisition, merger, consolidation, tender offer or other similar
significant transaction.

     2.5 Allocation of Expenses. The Company will pay all Registration Expenses of all
registrations under this Agreement; provided, however, that if a registration under
Section 2.1 is withdrawn at the request of the Initiating Holders, the Initiating Holders shall pay
the Registration Expenses of such registration pro rata in accordance with the number of their
Registrable Shares initially requested to have been included in such registration.

     2.6 Indemnification and Contribution.

          (a) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, the Company will, to the fullest extent permitted by law to the extent
provided for in this Section 2.6(a), indemnify and hold harmless each Selling Stockholder, each
underwriter of such Registrable Shares, each other Person, if any, who controls such Selling
Stockholder or underwriter within the meaning of the Securities Act or the Exchange Act, and each
of the foregoing Person’s Representatives from and against any loss, claim, damage, liability,
joint or several, attorney’s fees and costs and expenses of investigating, defending and settling
(to the extent required hereunder) any claim or Proceeding (collectively, the “Losses”) to which
such Selling Stockholder, underwriter, controlling person or their respective Representatives may
become subject under the Securities Act, the Exchange Act, state securities or Blue Sky laws or
otherwise, insofar as such Losses (or actions in respect thereof) arise out of or are based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in any
Registration Statement under which such Registrable Shares were registered under the Securities
Act, any Prospectus, or any amendment or supplement to such Registration Statement or Prospectus,
(ii) the omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, or (iii) any violation by the Company of
the Securities Act, Exchange Act or any Blue Sky law which relates to the offer and sale of
securities under such Registration Statement; and the Company will reimburse such Selling
Stockholder, underwriter, controlling person and their Representatives for any legal or other
expenses reasonably incurred by such Selling Stockholder, underwriter, controlling person or
Representative in connection with investigating, defending; settling (to the extent required
hereunder) or preparing to defend against or settle (to the extent required hereunder) any claim,
or Proceeding within 10 business days following receipt of an invoice evidencing such expenses in
reasonable detail; provided, however, that the Company will not be liable in any
such case to the extent that any such Loss (A) arises out of or is based upon

-13-

 

any untrue statement or omission made in such Registration Statement, Prospectus, or any such
amendment or supplement, in reliance upon and in conformity with information furnished to the
Company, in writing, by or on behalf of such Selling Stockholder, underwriter, controlling person
or their respective Representatives for use in such Registration Statement, Prospectus, amendment
or supplement, (B)-is caused by the failure of a Selling Stockholder to deliver a copy of the
Prospectus relating to such Registrable Shares, as then amended or supplemented, in connection with
a purchase, if the Company had previously furnished sufficient copies thereof to such Selling
Stockholder, (C) is caused by a Prospectus used during any suspension period provided by Sections
2.4(b) or 2.4(c), or (D) in which a Prospectus, as then amended and supplemented, has corrected any
such misstatement or omission and has been supplied to such Selling Stockholder with reasonable
notice of such amendment or supplement prior to the relevant sale or sales; provided further that
the obligations of the Company hereunder shall not apply to amounts paid in settlement of any such
Losses (or actions with respect thereof) if such settlement is effected without the consent of the
Company (which consent shall not be unreasonably withheld, conditioned or delayed).

          (b) In the event of any registration of any of the Registrable Shares under the Securities Act
pursuant to this Agreement, each Selling Stockholder, severally and not jointly, will, to the
extent provided for in this Section 2.6(b), indemnify and hold harmless the Company, each of its
directors and officers and each underwriter (if any) and each person, if any, who controls the
Company or any such underwriter within the meaning of the Securities Act or the Exchange Act,
against any Losses to which the Company, such directors and officers, underwriter or controlling
person may become subject under the Securities Act, Exchange Act, state securities or Blue Sky laws
or otherwise, insofar as such Losses (or actions in respect thereof) arise out of or are based upon
(i) any untrue statement or alleged untrue statement of a material fact contained in any
Registration Statement under which such Registrable Shares were registered under the Securities
Act, any Prospectus, or any amendment or supplement to the Registration Statement or Prospectus, or
(ii) any omission or alleged omission to state a material fact required to be stated therein or
necessary to make the statements therein not misleading, in each case, if and to the extent (and
only to the extent) that the statement or omission was made in reliance upon and in conformity with
information relating to such Selling Stockholder furnished in writing to the Company by or on
behalf of such Selling Stockholder or its Representative for use in such Registration Statement,
Prospectus, amendment or supplement; provided, however, that the obligations of
each Selling Stockholder hereunder shall be limited to an amount equal to the net proceeds to such
Selling Stockholder of Registrable Shares sold in connection with such registration;
provided further that the obligations of the Selling Stockholders hereunder shall
not apply to amounts paid in settlement of any such Losses (or actions with respect thereof) if
such settlement is effected without the consent of the Selling Stockholder (which consent shall not
be unreasonably withheld, conditioned or delayed).

          (c) Each Indemnified Party shall give notice to the Indemnifying Party promptly after such
Indemnified Party has knowledge of any claim as to which indemnity may be sought, and shall permit
the Indemnifying Party to assume the defense of any such claim or any Proceeding resulting
therefrom; provided, that the failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this Section 2.6 except to
the extent that the Indemnifying Party is materially and adversely affected by such failure. The
Indemnified Party may participate in such defense at such party’s expense;

-14-

 

provided, however, that the Indemnifying Party shall pay such expense if
representation of such Indemnified Party by the counsel retained by the Indemnifying Party would be
inappropriate under applicable ethical rules; provided, further, that the
Indemnifying Party shall pay the reasonable costs of investigation and reimbursement for costs and
expenses incurred by such Indemnified Party in preparation for and in giving testimony in any or in
anticipation of any Proceeding; provided, further, that in no event shall the
Indemnifying Party be required to pay the expenses of more than one law firm per jurisdiction as
counsel for such Indemnified Party. The Indemnifying Party shall also be responsible for the
expenses of such defense if the Indemnifying Party does not elect to assume such defense. No
Indemnifying Party will, without the prior written consent of the Indemnified Party, effect any
settlement of any claim or pending or threatened Proceeding in respect of which the Indemnified
Party is or has been threatened to be made a party and for which such Indemnified Party would be
entitled to indemnification hereunder, unless the settlement includes an unconditional release of
the Indemnified Party from all liability arising out of the action or inaction underlying the claim
or Proceeding. No Indemnified Party shall consent to entry of any judgment or settle such claim or
Proceeding without the prior written consent of the Indemnifying Party, which consent shall not be
unreasonably withheld, conditioned or delayed.

          (d) In order to provide for just and equitable contribution to joint liability under the
Securities Act in circumstances in which the indemnification provided for in this . Section 2.6 is
due in accordance with its terms but for any reason is held to be unavailable to an Indemnified
Party in respect to any Losses referred to herein, then the Indemnifying Party shall, in lieu of
indemnifying such Indemnified Party, contribute to the amount paid or payable as a result of Losses
to which such Indemnified Party may be subject in such proportions as is appropriate to reflect the
relative fault of the Company on the one hand and the Selling Stockholders on the other in
connection with the statements or omissions which resulted in such Losses, as well as any other
relevant equitable considerations. The relative fault of the Company and the Selling Stockholders
shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of material fact related to information supplied by the Company or the Selling
Stockholders and the parties’ relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. The Company and the Selling Stockholders agree that
it would not be just and equitable if contribution pursuant to this Section 2.6(d) were determined
by pro rata allocation or by any other method of allocation which does not take account of the
equitable considerations referred to above. Notwithstanding the foregoing, in no case shall any
one Selling Stockholder be obligated to contribute any amount in excess of the amount by which the
total price at which the Registrable Shares of the Selling Stockholder were offered to: the public
exceeds the amount of any Losses which the Selling Stockholder has otherwise paid by reason of such
untrue or alleged untrue statement or omission or alleged omission; provided,
however that no person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to contribution from any person or entity
who is not guilty of such fraudulent misrepresentation. Any party entitled to contribution will,
promptly after receipt of notice of commencement of any action, suit or proceeding against such
party in respect of which a claim for contribution may be made against another party or parties
under this Section 2.6(d), notify such party or parties from whom contribution may be sought. No
party shall be liable for contribution with respect to any action, suit, proceeding or claim
settled without its prior written consent, which consent shall not be unreasonably withheld,
conditioned or delayed. Each Selling Stockholder’s obligation to

-15-

 

contribute under Section 2.6(d) is several in the proportion that the proceeds of the offering
received by the Selling Stockholder bears to the total proceeds of the offering received by all the
Selling Stockholders, and not joint.

          (e) The rights and obligations of the Company and the Selling Stockholders under this Section
2.6 shall survive the termination of this Agreement.

          (f) An underwriter shall not be entitled to indemnification pursuant to this Section 2.6 in
the event that it fails to deliver Prospectus as required by the rules and regulations of the
Commission.

     2.7 Other Matters with Respect to Underwritten Offerings. In the event that
Registrable Shares are sold pursuant to a Registration Statement in an underwritten offering
pursuant to Section 2.1, the Company agrees to (a) enter into an underwriting agreement containing
customary representations and warranties with respect to the business and operations of an issuer
of the securities being registered and customary covenants and agreements to be performed by the
Company, including without limitation customary provisions with respect to indemnification by the
Company of the underwriters of such offering; (b) use its best efforts to cause its legal counsel
to render customary opinions to the underwriters with respect to the Registration Statement; and
(c) use its best efforts to cause its independent public accounting firm to issue customary “cold
comfort letters” to the underwriters with respect to the Registration Statement.

     2.8 Information by Holder. Each holder of Registrable Shares included in any
registration shall furnish in writing to the Company such information regarding such holder and the
distribution proposed by such holder as the Company may reasonably request and as shall be required
in connection with any registration, qualification or compliance referred to in this Agreement.
Notwithstanding any other provision of this Agreement, the Company shall have no obligation to
include Registrable Shares on any Registration Statement if the holder of such shares fails to
comply in a timely manner with this Section 2.8.

     2.9 Market “Stand-Off’ Agreement. Each Purchaser, if requested by the Company and the
managing underwriter of the Initial Public Offering by the Company of Common Stock, shall not sell
or otherwise transfer or dispose of any Registrable Shares or other securities of the Company
(excluding securities acquired in the Initial Public Offering or in the public market after such
offering) held by such Purchaser for a period not to exceed 180 days following the effective date
of the Registration Statement for the Initial Public Offering; provided, that all
stockholders then holding at least 5% of the outstanding Common Stock (on an as-converted basis)
and all officers and directors of the Company enter into similar agreements that are at least as
restrictive; provided, further, that if any such Person is released from the
obligations of any such agreement (or such obligations are waived), then all Purchasers shall be
similarly released (or shall have compliance similarly waived). The Company may impose
stop-transfer instructions with respect to the Registrable Shares or other securities subject to
the foregoing restriction until the end of such period. Any Purchaser receiving any written notice
from the Company regarding the Company’s plans to file a Registration Statement shall treat such
notice confidentially and shall not disclose such information to any person other than as necessary
to exercise its rights under this Agreement.

-16-

 

     2.10 Limitations on Subsequent Registration Rights. The Company shall not, without
the prior affirmative vote or written consent of Purchasers holding at least a majority of the
Registrable Shares (1) enter into any agreement (other than this Agreement) with any holder or
prospective holder of any securities of the Company which would allow such holder or prospective
holder to include securities of the Company in any Registration Statement, (2) grant any rights to
register securities of the Company which are senior or equal with respect to underwriter cutbacks
or (3) amend any existing agreement (other than this Agreement) with any holder, of any securities
of the Company relating to the registration of securities.

     2.11 Rule 144 Requirements. After the earliest of (a) the closing of the sale of
securities of the Company pursuant to a Registration Statement, (b) the registration by the Company
of a class of securities under Section 12 of the Exchange Act; or (c) the issuance by the Company
of an offering circular pursuant to Regulation A under the Securities Act, the Company agrees to:

               (i) comply with the requirements of Rule 144(c) under the Securities Act with respect to
current public information about the Company;

               (ii) file with the Commission in a timely manner all reports and other documents required of
the Company under the Securities Act and the Exchange Act (at any time after it has become subject
to such reporting requirements); and

               (iii) furnish to any holder of Registrable Shares upon request (A) a written statement by the
Company as to its compliance with the requirements. of said Rule 144(c), and the reporting
requirements of the Securities Act and the Exchange Act (at any time after it has become subject to
such reporting requirements), (B) a copy of the most recent annual or quarterly report of the
Company, and (C) such other reports and documents of the Company as such holder may reasonably
request to avail itself of any similar rule or regulation of the Commission allowing it to sell any
such securities without registration (and shall reimburse the holders for attorneys fees incurred
in connection with the provision of an opinion of counsel to the Company or its transfer agent in
connection with any sale by such holders under Rule 144).

     2.12 Termination. All of the Company’s obligations to register Registrable Shares under
this Agreement shall terminate on the. earlier to occur of (a) the date five years following the
consummation of the Initial Public Offering, or (b) as to any Purchaser, the date on which all
Registrable Shares held or entitled to be held upon conversion by such Purchaser may immediately be
sold under Securities Act Rule 144(k). No such termination shall affect the other rights and
obligations under this Agreement, including without limitation those under Section 2.6.
Notwithstanding anything to the contrary in this Agreement, the rights and obligations under
Section 2.6 will remain in place until the later of (a) the running of all applicable statutes of
limitations relating to claims regarding material misstatements or omissions in any Registration
Statement filed under the terms of Article 2 or (b) the final disposition of any claim asserting or
Proceeding involving an alleged material misstatement or omission in a Registration Statement which
is brought within the time period allowed in the applicable statute of limitations.

-17-

 

SECTION 3

PARTICIPATION RIGHTS

     3.1 Participation Rights.

          (a) The Company shall not issue, sell or exchange, agree to issue, sell or exchange, or
reserve or set aside for issuance, sale or exchange, any Offered Securities, unless in each such
case the Company shall have first complied with this Section 3.1. The Company shall deliver to
each Purchaser an Offer, which shall (i) identify and describe the Offered Securities, (ii)
describe the price and other terms upon which they are to be issued, sold or exchanged, and the
number or amount of the Offered Securities to be issued, sold or exchanged, (iii) identify the
persons or entities to which or with which the Offered Securities are to be offered, issued, sold
or exchanged and (iv) offer to issue and sell to or exchange with such Purchaser (A) such
Purchaser’s Basic Amount, and (B) such Purchaser’s Undersubscription Amount. Each Purchaser shall
have the right, for a period of 30 days following delivery of the Offer, to purchase or acquire, at
a price and upon the other terms specified in the Offer, the number or amount of Offered Securities
described above. The Offer by its terms shall remain open and irrevocable for such 30 day period.

          (b) To accept an Offer, in whole or in part, a Purchaser must deliver a Notice of Acceptance
to the Company prior to the end of the 30-day period of the Offer, setting forth the portion of the
Purchaser’s Basic Amount that such Purchaser elects to purchase and, if such Purchaser shall elect
to purchase all of its Basic Amount, the Undersubscription Amount (if any) that such Purchaser
elects to purchase. If the Basic Amounts subscribed for by all Purchasers are less than the total
of all Basic Amounts available for purchase, then each Purchaser who has set forth an
Undersubscription Amount in its Notice of Acceptance shall be entitled to purchase, in addition to
the Basic Amounts subscribed for, the Undersubscription Amount it has subscribed for;
provided, however, that should the Undersubscription Amounts subscribed for exceed
the Available Undersubscription Amount, each Purchaser who has subscribed for any Undersubscription
Amount shall be entitled to purchase only that portion of the Available Undersubscription Amount as
the Undersubscription Amount subscribed for by such Purchaser bears to the total Undersubscription
Amounts subscribed for by all Purchasers, subject to rounding by the Board of Directors to the
extent it reasonably deems necessary.

          (c) The Company shall have 90 days from the expiration of the period set forth in Section
3.1(a) above to issue, sell or exchange all or any part of the Refused Securities, but only to the
offerees or purchasers described in the Offer and only upon terms and conditions (including,
without limitation, unit prices and interest rates) which are not on the whole more favorable to
the acquiring person or persons or on the whole less favorable to the Company than those set forth
in the Offer.

          (d) In the event the Company shall propose to sell less than all the Refused Securities (any
such sale to be in the manner and on the terms specified in Section 3.1 (c) above), then each
Purchaser may, at his, her or its sole option and in his, her or its sole discretion, reduce the
number or amount of the Offered Securities specified in his, her or its Notice of Acceptance to an
amount that shall be not less than the number or amount of the Offered Securities that the

-18-

 

Purchaser elected to purchase pursuant to Section 3.1 (b) above multiplied by a fraction, (i)
the numerator of which shall be the number or amount of Offered Securities the Company actually
proposes to issue, sell or exchange (including Offered Securities to be issued or sold to
Purchasers pursuant to Section 3.1 (b) above prior to such reduction) and (ii) the denominator of
which shall be the original amount of the Offered Securities. In the event that, any Purchaser so
elects to reduce the number or amount of Offered Securities specified in his, her or its Notice of
Acceptance, the Company may not issue, sell or exchange more than the reduced number or amount of
the Offered Securities unless and until such securities have again been offered to the Purchasers
in accordance with Section 3.1 (a) above.

          (e) Upon the closing of the issuance, sale or exchange of all or less than all the Refused
Securities, the Purchasers shall acquire from the Company, and the Company shall issue to the
Purchasers, the number or amount of Offered Securities specified in the Notices of Acceptance, as
reduced pursuant to Section 3.1 (d) above if the Purchasers have so elected, upon the terms and
conditions specified in the Offer.

          (f) The purchase by the Purchasers of any Offered Securities is subject in all cases to the
preparation, execution and delivery by the Company and the Purchasers of a purchase agreement
relating to such Offered Securities reasonably satisfactory in form and substance to the Purchasers
and the Company.

          (g) Any Offered Securities not acquired by the Purchasers or other persons in accordance with
Section 3.1 (c) above may not be issued, sold or exchanged until they are again offered to the
Purchasers under the procedures specified in this Agreement.

          (h) The rights of the Purchasers under this Section 3 shall not apply to:

               (i) Common Stock issued as a-stock dividend to holders of Common Stock or upon any subdivision
or combination of shares of Common Stock;

               (ii) the issuance of any shares of Common Stock upon conversion of options, warrants, rights,
and convertible and exchangeable securities (as long as the applicable options, warrants, rights,
or convertible or exchangeable securities were outstanding on the date of this Agreement or were
issued thereafter in compliance with this Section 3.1);

               (iii) the issuance of shares of Common Stock, or options exercisable therefor, including
options outstanding on the date of this Agreement issued or issuable to officers, directors,
consultants and employees of the Company or any Subsidiary, as approved by a majority of the
members of the Board of Directors or any duly authorized committee of the Board of Directors
pursuant to any plan, agreement or arrangement approved by a majority of the members of the Board
of Directors of the Company;

               (iv) the issuance of securities in consideration for the acquisition (whether by merger or
otherwise) by the Company or any of its Subsidiaries of the stock or assets of any other entity;

               (v) the issuance of shares of Common Stock by the Company in an underwritten public offering
pursuant to an effective Registration Statement;

-19-

 

               (vi) the issuance of shares of Common Stock by the Company in connection with corporate
partnering transactions, lease lines, bank financings or acquisitions of business or intellectual
property rights, provided, that in each such case such transaction and issuance has been approved
by a majority of the members of the Board of Directors of the Company;

               (vii) securities as to which the Company has obtained a prior express written waiver of
application of this Section 3.1 from the holders of a majority of the Shares then outstanding; or

               (viii) any additional shares of Series C Preferred issued by the Company after the date of
this Agreement pursuant to the terms and conditions of the Purchase Agreement.

     3.2 Termination. This Section 3 shall terminate upon the earlier of the closing of
(i) a Company Sale (other than the transactions described in clauses (b)(i) and (c) of the
definition of a Company Sale) or (ii) the Initial Public Offering.

SECTION 4

COVENANTS OF THE COMPANY

     4.1 Affirmative Covenants. The Company covenants and agrees that, subject to waiver
or amendment in accordance with Section 6.4 below, it will perform and observe the following
covenants and provisions, and will cause each Subsidiary, if and when such Subsidiary exists, to
perform and observe such of the following covenants and provisions as are applicable to such
Subsidiary:

          (a) Payment of Taxes. The Company and each Subsidiary will pay and discharge all
lawful taxes, assessments and governmental charges or levies imposed upon it or upon its income or
property before the date on which penalties attach thereto, and all lawful claims which, if unpaid,
would become a lien or charge on any properties of the Company or any Subsidiary; provided,
however, that neither the Company nor any Subsidiary will be required to pay any tax,
assessment, charge, levy or claim which is being contested in good faith and by appropriate
proceedings if the Company or the Subsidiary will have set aside on its books reserves, if any, to
the extent required by U.S. generally accepted accounting principles with respect thereto. All
transfer, excise or other taxes payable to any jurisdiction (in the United States and outside of
the United States) or by reason of the sale. or issuance of the Shares (except for such taxes
payable by reason of any subsequent transfer of the Shares) shall be paid or provided for by the
Company.

          (b) Maintenance of Insurance. The Company shall maintain, or shall cause to be
maintained valid policies of workers’ compensation insurance and insurance with responsible and
reputable insurance companies or associations in such amounts, types and covering such risks as are
acceptable to the Board of Directors of the Company and are customarily carried by companies
engaged in similar businesses and owning similar properties in the same general areas in which the
Company or such Subsidiary operates, including, without limitation, insurance

-20-

 

against loss, damage, fire, theft, public liability, products liability, clinical trial
liability and other risks.

          (c) Preservation of Corporate Existence and Intellectual Property Rights. The Company
and each Subsidiary shall preserve and maintain its corporate existence, rights, franchises and
privileges in the jurisdiction of its incorporation, and shall qualify and remain qualified, and
cause each Subsidiary to qualify and remain qualified, as a foreign corporation in each
jurisdiction in which such qualification is necessary or desirable in view of its business and
operations or the ownership or lease of its properties and the failure to so qualify, individually
or in the aggregate, would have a material adverse effect on the business, properties, assets,.
liabilities (contingent or otherwise) or condition (financial or otherwise) or results of
operations of the Company and its Subsidiaries as a whole (a “Company Material Adverse
Effect”), provided that Xairo may change its domicile to the United States by way of merger
with a U.S. Subsidiary or the Company or otherwise, or be merged into the Company or any Subsidiary
of the Company. The Company shall, and shall cause each Subsidiary to, secure, preserve and
maintain all Intellectual Property Rights (as defined in the Purchase Agreement) owned or possessed
by it, except where the failure to so secure, preserve and maintain such intellectual Property
Rights would not have a material adverse effect on the business, properties, assets, liabilities
(contingent or otherwise) or condition (financial or otherwise), or results of operations of the
Company and its Subsidiaries, taken as a whole.

          (d) Inspection Rights. The Company shall, at any time during normal business hours
and upon reasonable prior notice to the Company; permit any Purchaser holding at least 10,000,000
shares of Series B Preferred or Series C Preferred, or its designated Representative, to (i) visit
and inspect the premises and any of the properties of the Company and any Subsidiary, including its
records and books of account (and make copies thereof and take extracts therefrom), and (ii)
discuss the affairs, finances and accounts of the Company and any Subsidiary with its officers,
directors, employees and accountants, all at the expense of such Purchaser; provided, that
the Company shall not be obligated under this Section 4.1 (d) with respect to a Competitor or with
respect to information whose disclosure would adversely affect attorney-client privilege with
respect to such information; provided, further, that the Company shall not be
obligated under this Section 4.1(d) with respect to any information which the Board of Directors
determines in good faith is confidential and should not be disclosed unless the applicable
Purchaser executes a confidentiality agreement in form and substance reasonably acceptable to the
Company. The disclosure of information to a Purchaser’s Representative (unless such Representative
is a Competitor), shall be permitted so long as the Purchaser informs such Persons that the
information is confidential and subject to an ongoing obligation to keep such information
confidential and such Representative agrees or has agreed to keep such information confidential
(either specifically or in general).

          (e) Board Observer. So long as the holders of the Series B Registrable Shares
continue to hold, in the aggregate, at least 50% of the Series B Registrable Shares outstanding on
the date hereof, the Company will permit one observer (who shall not be an Affiliate or
Representative of any Competitor) selected by the holders of a majority of the Series B Registrable
Shares to attend all meetings of the Board of Directors of the Company, and shall provide such
observer with such notice and. other information with respect to such meetings as are delivered to
the directors of the Company; provided, however, that such observer shall not be

-21-

 

permitted to attend any meeting or portion thereof or have access to such other information
if, in the judgment of the Company under advice of counsel, (i) such observer’s presence or receipt
of such information would not be in the best interest of the Company due to the sensitive or highly
confidential nature of the proceedings or information presented or (ii) such observer’s presence or
receipt of such information would adversely affect attorney-client privilege with respect to such
meeting or information.

          (f) Litigation and FDA Notices. The Company will promptly provide written notice to
the Purchasers of any litigation or government proceeding or investigation pending or threatened
against the Company or any Subsidiary or against any officer, director, any person in charge of a
principal business function or any other individual designated by the Board of Directors as a key
employee or principal stockholder of the Company or any Subsidiary with potential liability in
excess of $100,000. The Company will also promptly provide to each Purchaser written notice and
copies of any adverse or potentially adverse notices or correspondence from the Food and Drug
Administration or foreign regulatory equivalent.

          (g) Confidential and Proprietary Information and Non-Competition Agreement. The
Company will require each person now or hereafter employed by the Company or any Subsidiary with
access to confidential and proprietary information of the Company to enter into an agreement
covering confidentiality, non-solicitation, non-competition and assignment of inventions in
substantially the form attached hereto as Exhibit E to the Purchase Agreement.

          (h) Keeping of Records and Books of Account. The Company and each Subsidiary shall
keep adequate records and books of account in which complete entries will be made in accordance
with generally accepted accounting principles, reflecting all financial transactions of the Company
and any Subsidiary, and in which, for each fiscal year, all proper reserves for depreciation,
depletion, returns of merchandise, obsolescence, amortization, taxes, bad debts and other purposes
in connection with its business shall be made.

          (i) Budget Approval. At least 30 days prior to the commencement of each fiscal year,
prepare and submit to, and obtain in respect thereof the approval from the Board of Directors and
the Purchasers holding at least a majority of the outstanding Series C Preferred, the operating
budgets, operating expenses, profit and loss projections, cash flow projections and a capital
expenditure budget (the “Annual Budget”) for the succeeding fiscal year.

          (j) Reservation of Conversion Stock. The Company will, upon any increase in the
number of shares of Common Stock issuable upon conversion of the Series B Preferred or Series C
Preferred, reserve additional shares of Common Stock for issuance upon such conversion, so that the
number of shares of Common Stock so reserved will not at any time be less than the number of such
shares issuable upon such conversion.

          (k) Compliance with Laws. The Company will comply with the requirements of all
applicable laws, rules, regulations and orders of any governmental authority, where noncompliance
would have a material adverse effect on the business, properties, assets, liabilities (contingent
or otherwise) or condition (financial or otherwise), or results of operations of the Company and
its Subsidiaries, taken as a whole.

-22-

 

     4.2 Financial Statements and Other Information. The Company will deliver to each
Purchaser, individually or collectively with its affiliates, copies of the following:

          (a) as soon as practicable, but in any event within 90 days after the end of each fiscal year
of the Company, (i) audited balance sheets of the Company as at the end of such year, together with
audited statements of income and retained earnings and statements of cash flows of the Company for
such year, together with notes related thereto, each prepared in accordance with United States
generally accepted accounting principles, consistently applied, and setting out in each case in
comparative form the figures for the previous fiscal year, all in reasonable detail and certified
by certified independent public accountants of established national reputation selected by the
Board of Directors of the Company or the audit committee thereof and (ii) a report of the principal
financial officer of the Company containing a management discussion and analysis of the Company’s
consolidated financial condition at the end of such year and the results of operations for such
year, including, but not limited to, a description of significant events with respect to the
Company and its Subsidiaries, if any, during the preceding year and any planned or anticipated
significant activities or events during the next fiscal quarter;

          (b) as soon as practicable, but in any event within 45 days after the end of each of the first
three fiscal quarters of the Company in each year, (i) an unaudited balance sheet at the end of
such quarter, and unaudited statements of profit and loss, of changes in financial condition and of
cash flow for such period and for the current fiscal year to date, and comparisons to the Annual
Budget and to corresponding periods for prior fiscal years, in each case prepared in accordance
with United States generally accepted accounting principles, consistently applied (other than for
accompanying notes and subject to changes resulting from year-end audit adjustments), and (ii) a
report of the principal financial officer of the Company containing a management discussion and
analysis of the Company’s consolidated financial condition at the end of such quarter and the
results of operations for such quarter and the year to date, including, but not limited to, a
description of significant events with respect to the Company and its Subsidiaries, if any, during
such periods and any planned or anticipated significant activities or events during the next fiscal
quarter;

          (c) as soon as practicable, but in any event within 30 days after the end of each month, an
unaudited balance sheet at the end of such quarter, and unaudited statements of profit and loss, of
changes in financial condition and of cash flow for such month and for the current fiscal year to
date, and comparisons to the Annual Budget and to corresponding periods for prior fiscal years, in
each case prepared in accordance with United States generally accepted accounting principles,
consistently applied (other than for accompanying notes and subject to changes resulting from
year-end audit adjustments);

          (d) Together with each delivery required under Sections 4.2(a), (b) and (c), a Compliance
Certificate in the form attached as Exhibit C executed on behalf of the Company by the
Chief Executive Officer and the Chief Financial Officer of the Company; provided,
however, that nothing contained in such certificate shall provide the basis for or
otherwise result in any personal liability, obligation or other Loss to the Chief Executive Officer
or the Chief Financial Officer of the Company, and each Purchaser expressly waives the right to
bring any personal claim, action or other proceeding against the Chief Executive Officer or Chief
financial Officer of the Company relating thereto; and

-23-

 

          (e) with reasonable promptness, such other information and materials customarily provided or
reasonably requested, including, without limitation, copies of all management letters,
communications with stockholders or directors, press releases and Registration Statements.

     The foregoing financial statements shall be prepared on a consolidated basis if the Company
then has any Subsidiaries.

     4.3 Negative Covenants of the Company. The Company agrees that it will not take the
following actions without the prior affirmative vote or prior written consent of the holders of a
majority of the then outstanding shares of Series C Preferred and Series B Preferred that are held
by Persons other than Competitors, voting together as a single class (on an as converted basis):

          (a) Enter into any transaction with any of its Affiliates, directors, officers or employees
(or their respective family members) except employment and director arrangements entered into in
the ordinary course of business that do not require separate approval under paragraph (e) of this
Section 4.3, advances and similar expenditures in the ordinary course of business or under the
terms of an employee stock or option plan approved by the Board of Directors;

          (b) Enter into any transaction or series of related transactions in which the Company will be
obligated to pay in excess of $1,000,000 in any 12 month period;

          (c) incur, guarantee, act as a surety for or otherwise become obligated for any indebtedness
for borrowed money, singularly or which together with any other indebtedness for borrowed money (or
guarantee or surety) exceeds $1,000,000;

          (d) Grant any security interest in, pledge or allow or suffer any lien to be placed on, any
assets of the Company except for capital leases entered into or purchase money security interests
or mechanics liens incurred in the ordinary course of business provided that any such mechanics
liens that are not contested by the Company in good faith are discharged within 60 days of their
imposition;

          (e) Enter into employment agreements containing any separation or severance benefits, or amend
any existing or subsequently existing employment agreements in any material respect;

          (f) Adopt or amend any stock option, stock appreciation, restricted stock or other equity
incentive plan, or increase the number of shares or other rights available under existing plans or
arrangements for the grant of stock options, stock appreciation rights, restricted stock or other
similar equity incentives;

          (g) Approve or consummate a Company Sale to any Person or group of affiliated Persons;

-24-

 

          (h) Sell, transfer or otherwise dispose of any line of business, or sell, transfer, license or
otherwise dispose of any of the material assets of the Company except in the ordinary course of
business;

          (i) Amend, modify, terminate, waive or otherwise alter, in whole or in part, any agreement
covering confidentiality, non-solicitation, non-competition or assignment of inventions between the
Company and any officer, director, employee or consultant except in the ordinary course of business
without causing a Company Material Adverse Effect;

          (j) Grant to any of its or any Subsidiary’s employees, consultants, officers, directors or
affiliates options to purchase shares of Common Stock which will become exercisable at a rate in
excess of 33% per annum from the date of the grant, the first such vesting to occur no earlier than
6 months from the date of issuance;

          (k) Issue, sell or grant any right to purchase any Offered Securities at less than the fair
market value of such Offered Securities on the date of the issue, sale or grant, as determined in
good faith by the Board;

          (l) Enter into any contract, agreement or understanding relating to the employment, separation
or termination of any officer or employee of the Company calling for the payment of any sums or
other benefits to a Person in an amount in excess of $500,000 during any fiscal year of the
Company;

          (m) Acquire whether by merger, consolidation or otherwise, the assets or securities of any
other Person outside of the ordinary course of the Company’s business;

          (n) Enter into any joint venture, partnership or other strategic alliance which requires the
investments, expenditures or contributions of cash, property or services by the Company or any
Subsidiary with an aggregate value in excess of $1,000,000 during any fiscal year or $3,000,000 in
the aggregate, in each case as determined in good faith by the Board of Directors;

          (o) Allow any Subsidiary to take any action that would be prohibited under this Section 4.3 if
taken by the Company;

          (p) Effect an Initial Public Offering that is not a Qualified IPO; or

          (q) Amend, modify, terminate, waive or otherwise alter, in whole or in part, the Restructuring
Agreement of even date with this Agreement among the Company, Elan and certain of Elan’s Affiliates
(the “Restructuring Agreement”), the Option Agreement entered into pursuant to the
Restructuring Agreement, or the “Elan License Agreement” (as defined in the Restructuring
Agreement).

     4.4 Termination of Covenants. This Section 4 shall terminate upon the earlier of the
closing of (i) a Company Sale (other than the transactions described in clauses (b)(i) and (c) of
the definition of a Company Sale) or (ii) the Initial Public Offering.

-25-

 

SECTION 5

TRANSFERS OF RIGHTS

     5.1 Transfers of Rights under this Agreement. The rights granted to the Purchasers
under this Agreement may only be transferred or assigned by a Purchaser to any person or entity to
which Registrable Shares are transferred by such Purchaser in compliance with the requirements of
the Stockholders’ Agreement, and such transferee shall be deemed a “Purchaser” for purposes of this
Agreement; provided, that the assignment of rights shall be contingent upon the transferee
providing a written instrument to the Company notifying the Company of such transfer and agreeing
in writing to be bound by all terms and conditions set forth in this Agreement prior to the
exercise of any rights hereunder and in any case within 30 days of written request by the Company;
provided, further, that no such assignment of rights may be made to any Competitor
without the express written approval of the Board of Directors, which approval maybe withheld in
its sole discretion. The rights and obligations of the Company under this Agreement may not be
assigned or delegated by the Company.

SECTION 6

MISCELLANEOUS

     6.1 Notices. All notices, requests, consents, and other communications under this
Agreement shall be in writing and shall be deemed delivered (a) three business days after being
sent by registered or certified mail, return receipt requested, postage prepaid, (b) one business
day after being sent via a reputable nationwide overnight courier service guaranteeing next
business day delivery or (c) upon delivery when sent by facsimile (with confirmation of receipt),
in each case to the intended recipient as set forth below:

     If to the Company:

Iomai Corporation

20 Firstfield Road, Suite 250

Gaithersburg, Maryland 20878

Attention: President

Fax: 301-556-4501

or at such other address as may have been furnished in writing by the Company to the other parties
hereto, with a copy to:

Ropes & Gray

One International Place

Boston, MA 02110-2624

Attention: Paul M. Kinsella

Fax: (617) 951-7050

     If to a Purchaser, at its address set forth on the Purchaser Signature Page attached hereto,
or at such other address as may have been furnished in writing by such Purchaser to the

-26-

 

Company, with, in the case of each Purchaser other than Elan International Services, Ltd. or
its Affiliates, a copy to:

Baker & McKenzie

130 East Randolph Drive

Chicago, IL 60601

Attention: Bruce Zivian

Fax: 312-861-2899

     Any party may give any notice, request, consent or other communication under this Agreement
using any other means (including, without limitation, personal delivery, messenger service,
telecopy, first class mail or electronic mail), but no such notice, request, consent or other
communication shall be deemed to have been duly given unless and until it is actually received by
the party for whom it is intended. Any party may change the address to which notices, requests,
consents or other communications hereunder are to be delivered by giving the other parties notice
in the manner set forth in this Section.

     6.2 Successors and Assigns. Except as otherwise expressly provided herein, the
provisions of this Agreement shall inure to the benefit of, and be binding upon, the respective
successors, assigns, heirs, executors, and administrators of the parties hereto.

     6.3 Entire Agreement. This Agreement, the Stockholders’ Agreement and the Purchase
Agreement contain the entire agreement and understanding between the parties hereto with respect to
the subject matter hereof and supersede all prior agreements and understandings, written or oral,
relating to such subject matter, including without limitation, the Old Registration Rights
Agreement.

     6.4 Amendments and Waivers. Except as otherwise expressly set forth in this
Agreement, any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or
prospectively), with the written consent of the Company and the holders of at least 60% of the
Registrable Shares. Any amendment or waiver shall be binding upon each holder of Registrable
Shares and the Company. No waivers of or exceptions to any term, condition or provision of this
Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or
continuing waiver of any such term, condition or provision.

     6.5 Counterparts. This Agreement may be executed in one or more counterparts,
including by facsimile copy, each of which shall be deemed to be an original, but all of which
shall be one and the same document.

     6.6 Severabilitv. The invalidity or unenforceability of any provision of this
Agreement shall not affect the validity or enforceability of any other provision of this Agreement.
Any provision of this Agreement held invalid or unenforceable only in part or degree will remain
in full force and effect to the extent not held invalid or unenforceable.

     6.7 Specific Performance. In addition to any and all other remedies that may be
available at law in the event of any breach of this Agreement, each Purchaser shall be entitled to

-27-

 

specific performance of the agreements and obligations of the Company hereunder and to such
other injunctive or other equitable relief, without the requirement of the posting of a bond, as
may be granted by a court of competent jurisdiction. The Company and the Purchasers. acknowledge
and agree that the Purchasers could be damaged irreparably if any of the provisions of this
Agreement are not performed according to their specific terms and that any breach of this Agreement
could not be adequately compensated in all cases by monetary damages alone.

     6.8 Governing Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be
governed by and construed in. accordance with the laws of the State of Delaware and the laws of the
United States applicable therein (in each case without giving effect to any choice or conflict of
laws provision or rule that would cause the application of the laws of any other jurisdiction) and
shall be treated in all respects as a Delaware contract. Any action, suit or proceeding arising
out of or relating to this Agreement shall be brought in the state courts of the State of Delaware,
or, if it has or can acquire jurisdiction, any Federal court located in such State, and each of the
parties hereto hereby irrevocably submits to the exclusive jurisdiction of such courts and waives
trial by jury.

     6.9 Titles and Subtitles. The titles of the sections and subsections of this
Agreement are for convenience of reference only and are not to be considered in construing this
Agreement.

     6.10 Confidentiality. Each Purchaser agrees that it will keep confidential and shall
not disclose any information (so long as such information is not in the public domain) provided by
the Company to such Purchaser in connection with this Agreement, except that such Purchaser may
disclose such confidential information to any Affiliate or Representative for the purpose of
evaluating its investment in the Company as long as such Affiliate or Representative is advised of
the confidentiality provisions of this Agreement and agrees or has agreed to keep such information
confidential.

     6.11 Additional Purchasers. Notwithstanding anything to the contrary contained
herein, if the Company shall issue additional shares of its Series C Preferred pursuant to the
Purchase Agreement, any Additional Purchaser (as defined in the Purchase Agreement) who becomes a
party to the Purchase Agreement shall automatically become a party to this Agreement by executing
and delivering to the Company the Purchaser Signature Page attached to the Purchase Agreement,
which shall serve as a counterpart to this Agreement by which such Additional Purchaser agrees to
be bound by the obligations imposed under this Agreement. Upon such execution and delivery, such
Additional Purchaser shall be deemed a “Purchaser” hereunder and Exhibit A hereto shall
automatically be amended to add such Additional Purchaser as a party to this Agreement.

     6.12 Section Heading and References. The section headings are for the convenience of
the parties and in no way alter, modify, amend, limit or restrict the contractual obligations of
the parties. Any reference in this Agreement to a particular section or subsection shall refer to
a section or subsection of this Agreement, unless specified otherwise.

     6.13 Further Assurances. The parties agree to execute and deliver to each other
documents and to do other acts and things, all as the other party may reasonably request for the
purpose of carrying out the intent of this Agreement.

-28-

 

     6.14 Omissions; Cumulative Rights. The rights and remedies of the parties to this
Agreement are cumulative and not alternative. Except as set forth in this Agreement, no failure or
delay by any party in exercising any right, power, or privilege under this Agreement will operate
as a waiver of the right, power, or privilege, and no single or partial exercise of any right,
power, or privilege will preclude any other or further exercise of the right, power, or privilege
or the exercise of any other right, power, or privilege. To the maximum extent permitted by
applicable law (a) no claim or right arising out of this Agreement can be discharged by one party,
in whole or in part, by a waiver or renunciation of the claim or right unless in writing, (b) no
waiver that may be given by a party will be applicable except in the specific instance for which it
is given and (c) no notice to or demand on one party will be deemed to be a waiver of any
obligation of that party or of the right of the party giving such notice or demand to take further
action without notice or demand as provided in this Agreement or the documents referred to in this
Agreement.

[Remainder of page intentionally left blank.]

-29-

 

INVESTOR RIGHTS AGREEMENT

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written
above.

	 	 	 	 	 
	 	IOMAI CORPORATION

 	 
	 	By:  	/s/ Stanley C. Erck
 	 
	 	 	Name:  	Stanley C. Erck 	 
	 	 	Title:  	Chief Executive Officer and President 	 
	 

[Purchaser Signatures for this Agreement are included in the

Purchaser Signature Page to the Purchase Agreement also attached hereto]

 

 

IOMAI CORPORATION

INVESTOR RIGHTS AGREEMENT SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the Investor Rights Agreement
dated as of the date hereof and authorizes this signature page to be attached to the Investor
Rights Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	     Elan International Services, Ltd.     
	 	 	Print Name of Purchaser
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Kevin Insley
	 	 	 	 	 

	 	 	 	 	Name: Kevin Insley
	 	 	 	 	Title: President
	 	 	Record Address:	 	     102
St. James Court

     Flats, Smith Parish
	 

	 	 	 	 	 	     Bermuda, FL 04
	 	 	Telephone
No.: 441-292-9169
	 	 	Facsimile
No.: 441-229-2224
	 	 	E-mail
Address: Kevin.insley@Elan.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: December, 2002	 	Alexandria Real Estate Equities, L.P.
	 
	 	 	 	 	 	 
	 	 	By:     ARE-QRS CORP., its general partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/Joel S. Marcus
	 	 	 	 	     Name:    Joel S. Marcus
	 	 	 	 	     Title:      Chief Executive Officer
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	135 North Los Robles Avenue
	 	 	Suite 250
	 	 	Pasadena, CA 91101
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	(626) 578-0777
	 	 	Facsimile No.:	 	(626) 578-0770
	 	 	E-mail Address:	 	jmarcus@labspace.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	CNF Investments, LLC
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Robert J. Flanagan
	 	 	 	 	Name: Robert J. Flanagan
	 	 	 	 	Title:   Manager
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	7500 Old Georgetown Road
	 	 	Bethesda, Maryland 20016
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	301-657-7131
	 	 	Facsimile No.:	 	301-657-7263
	 	 	E-mail Address:	 	RFlan@ClarkUS.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	Domain Partners V, L.P.
	 
	 	 	 	 	 	 
	 	 	By: One Palmer Square Associates V, L.L.C.
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Jesse I. Treu
	 	 	 	 	Name: Jesse I. Treu
	 	 	 	 	Title: Managing Member
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	One Palmer Square
	 	 	Suite 515
	 	 	Princeton, NJ 08542
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	609-683-5656
	 	 	Facsimile No.:	 	609-683-9789
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	DP V Associates, L.P.
	 
	 	 	 	 	 	 
	 	 	By: One Palmer Square Associates V, L.L.C.,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Jesse I. Treu
	 	 	 	 	Name: Jesse I. Treu
	 	 	 	 	Title: Managing Member
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	One Palmer Square
	 	 	Suite 515
	 	 	Princeton, NJ 08542
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	609-683-5656
	 	 	Facsimilen No.:	 	609-683-9789
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	Essex Woodlands Health Ventures V, L.P.
	 
	 	 	 	 	 	 
	 	 	By: Essex Woodlands Health Ventures V, L.L.C.,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Immanuel Thangaraj
	 	 	 	 	Name: Immanuel Thangaraj
	 	 	 	 	Title:   Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	190 South LaSalle Street
	 	 	Suite 2800
	 	 	Chicago, IL 60603
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	312-444-6019
	 	 	Facsimile No.:	 	312-444-6034
	 	 	E-mail Address:	 	ithangaraj@essexwoodlands.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/3/02	 	FBR Infinity II Ventures (Israel) LP
	 
	 	 	 	 	 	 
	 	 	By: FBR Infinity II Partners, L.P.
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Amiz Ealor
	 	 	 	 	Name: Amiz Ealor
	 	 	 	 	Title:
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	3 Azrieli Center
	 	 	Triangle Tower
	 	 	42nd Floor
	 	 	Tel Aviv
	 	 	67023
	 	 	Israel
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	972-3-6075456
	 	 	Facsimile No.:	 	972-3-6075455
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/3/02	 	FBR Infinity II Ventures LP
	 
	 	 	 	 	 	 
	 	 	By: FBR Infinity II Partners, L.P.
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Amiz Ealor
	 	 	 	 	Name: Amiz Ealor
	 	 	 	 	Title:
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	3 Azrieli Center
	 	 	Triangle Tower
	 	 	42nd Floor
	 	 	Tel Aviv
	 	 	67023
	 	 	Israel
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	972-3-6075456
	 	 	Facsimile No.:	 	972-3-6075455
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/3/02	 	FBR Infinity II Ventures (Erisa) LP
	 
	 	 	 	 	 	 
	 	 	By: FBR Infinity II Partners, L.P.
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Amiz Ealor
	 	 	 	 	Name: Amiz Ealor
	 	 	 	 	Title:
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	3 Azrieli Center
	 	 	Triangle Tower
	 	 	42nd Floor
	 	 	Tel Aviv
	 	 	67023
	 	 	Israel
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	972-3-6075456
	 	 	Facsimile No.:	 	972-3-6075455
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	Global Capital Finance GmbH + Co. Europe K6
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Paul R. Hofer
	 	 	 	 	Name: Paul R. Hofer
	 	 	 	 	Title:   Managing Director
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Urban Schnerzmann
	 	 	 	 	Name: Urban Schnerzmann
	 	 	 	 	Title:   Vice President
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	Kanalstrasse 31
	 	 	8157 Glattbrugg, Switzerland
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	+411 8086016
	 	 	Facsimile No.:	 	+411 8086019
	 	 	E-mail Address:	 	uschwerzmann@globalcapitalfinance.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/2/02	 	MedImmune Ventures, Inc.
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Wayne T. Hockmeyer
	 	 	 	 	Name: Wayne T. Hockmeyer
	 	 	 	 	Title:    President
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	35 West Watkins Mill Road
	 	 	Gaithersburg, MD 20878
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	301-527-4250
	 	 	Facsimile No.:	 	240-632-4030
	 	 	E-mail Address:	 	hockmeyerw@medimmune.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	New Enterprise Associates 10, Limited Partnership
	 
	 	 	 	 	 	 
	 	 	By: NEA Partners 10, Limited Partnership,
	 	 	its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Eugene A. Trainor, III
	 	 	Name:	 	Eugene A. Trainor, III
	 	 	Title:	 	Administrative General Partner
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	119 St. Paul Street
	 	 	Baltimore, MD 21202
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	410-244-0115
	 	 	Facsimile No.:	 	410-752-7721
	 	 	E-mail Address:	 	gtrainor@____.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	NEA Ventures 2002, Limited Partnership
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Pamela J. Clark
	 	 	Name:	 	Pam Clark
	 	 	Title:	 	General Partner
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	119 St. Paul Street
	 	 	Baltimore, MD 21202
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	410-244-0115
	 	 	Facsimile No.:	 	410-752-7721
	 	 	E-mail Address:	 	pclark@nea.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 11/27/02	 	ProQuest Investments II, L.P.
	 
	 	 	 	 	 	 
	 	 	By: ProQuest Associates II LLC,
	 	 	its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Pasquale
DeAngelis
	 	 	Name:	 	Pasquale DeAngelis
	 	 	Title:	 	Chief Financial Officer
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	600 Alexander Park
	 	 	Suite 204
	 	 	Princeton, NJ 08540
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	609-919-3567
	 	 	Facsimile No.:	 	609-375-1047
	 	 	E-mail Address:	 	p___@proquestvc.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 11/27/02	 	ProQuest Investments II Advisors Fund, L.P.
	 
	 	 	 	 	 	 
	 	 	By: ProQuest Associates II LLC,
	 	 	its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Pasquale DeAngelis
	 	 	Name:	 	Pasquale DeAngelis
	 	 	Title:	 	Chief Financial Officer
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	600 Alexander Park
	 	 	Suite 204
	 	 	Princeton, NJ 08540
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	609-919-3567
	 	 	Facsimile No.:	 	609-375-1047
	 	 	E-mail Address:	 	p___@proquestvc.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date:                                         	 	SAM Sustainability Private Equity, LP
	 
	 	 	 	 	 	 
	 	 	By: SAM Equity Partners Ltd.
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Christopher Cochrane and Pascal Mahieux
	 	 	Name:	 	Christopher Cochrane and Pascal Mahieux
	 	 	Title:	 	Directors
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	P. O. Box 255
	 	 	Trafalgar Square/Les Banques
	 	 	St. Peter Port, Guernsey/Channel Islands
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	+44 1481 745 001
	 	 	Facsimile No.:	 	+44 1481 745 074
	 	 	E-mail Address:	 	pascal.mahieux@gfm.com
	 

	 	 	 	 	 	Chris.cochrane@gfm.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 11/27/02	 	Technology Partners Fund VI, L.P.
	 
	 	 	 	 	 	 
	 	 	By:	 	TP Management VI, L.L.C.
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ James Glasheen
	 	 	Name:	 	James Glasheen
	 	 	Title:	 	Member
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	1550 Tiburon Blvd.
	 	 	Suite A
	 	 	Belvedere, CA 94920
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	650-289-9000
	 	 	Facsimile No.:	 	650-289-9001
	 	 	E-mail Address:	 	jim@technologypartners.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 11/27/02	 	Technology Partners Fund VII, L.P.
	 
	 	 	 	 	 	 
	 	 	By:	 	TP Management VII, L.L.C.
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ James Glasheen
	 	 	Name:	 	James Glasheen
	 	 	Title:	 	Member
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	1550 Tiburon Blvd.
	 	 	Suite A
	 	 	Belvedere, CA 94920
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	650-289-9000
	 	 	Facsimile No.:	 	650-289-9001
	 	 	E-mail Address:	 	jim@technologypartners.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 11/27/02	 	Technology Partners Affiliates VII, L.P.
	 
	 	 	 	 	 	 
	 	 	By:	 	TP Management VII, L.L.C.
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ James Glasheen
	 	 	Name:	 	James Glasheen
	 	 	Title:	 	Member
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	1550 Tiburon Blvd.
	 	 	Suite A
	 	 	Belvedere, CA 94920
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	650-289-9000
	 	 	Facsimile No.:	 	650-289-9001
	 	 	E-mail Address:	 	jim@technologypartners.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/16/02	 	ETP/FBR Venture Capital II, LLC
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Weiwu He
	 	 	Name:	 	Weiwu He
	 	 	Title:	 	General Partner
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	1901 Research Blvd., Ste. 350
	 	 	Rockville, MD 20850
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	301-222-2203
	 	 	Facsimile No.:	 	301-222-2221
	 	 	E-mail Address:	 	whe@etpvc.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/20/02	 	China Development Industrial Bank Inc.
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Tze-Kaing Yang
	 	 	Name:	 	Tze-Kaing Yang
	 	 	Title:	 	President
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	125, Nanking East Road,
	 	 	Section 5, Taipei 105, Taiwan, R.O.C.
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	886-2-2768-6655
	 	 	Facsimile No.:	 	886-2-2756-6918
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 12/26/02	 	Pan-Pacific Venture Capital Co., Ltd.
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ David Y.S. Chao
	 	 	Name:	 	David Y.S. Chao
	 	 	Title:	 	President
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	6F, No. 21, Lane 120, Neibu Rd.
	 	 	Sec. 1, Taipei 114, Taiwan, ROC
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	02-8751.1155 Ext. 8033
	 	 	Facsimile No.:	 	02-8751.1212
	 	 	E-mail Address:	 	dchao@pvcc.com.tw

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 02/16/03	 	AIG Private Equity Portfolio, L.P.
	 
	 	 	 	 	 	 
	 	 	By: AIG Global Investment Corp., as Manager
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ David Pinkerton
	 	 	Name:	 	David Pinkerton
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	175 Water Street, 26th Floor
	 	 	New York, New York 10038
	 	 	Attn: Astrid S. Tuminez
	 	 	Telephone No.:	 	212-458-2318
	 	 	Facsimile No.:	 	212-458-2250
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 02/16/03	 	AIG Private Equity Portfolio II, L.P.
	 
	 	 	 	 	 	 
	 	 	By: AIG Global Investment Corp., as Manager
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ David Pinkerton
	 	 	Name:	 	David Pinkerton
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	175 Water Street, 26th Floor
	 	 	New York, New York 10038
	 	 	Attn: Astrid S. Tuminez
	 	 	Telephone No.:	 	212-458-2318
	 	 	Facsimile No.:	 	212-458-2250
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 02/16/03	 	AIG Horizon Partners Fund, L.P.
	 
	 	 	 	 	 	 
	 	 	By: AIG Horizon Partners GP, L.P.,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By: AIG Horizon Partners, LLC,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By: AIG Global Investment Corp., its Manager
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ David Pinkerton
	 	 	Name:	 	David Pinkerton
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	175 Water Street, 26th Floor
	 	 	New York, New York 10038
	 	 	Attn: Astrid S. Tuminez
	 	 	Telephone No.:	 	212-458-2318
	 	 	Facsimile No.:	 	212-458-2250
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 02/16/03	 	AIG Horizon Side-by-Side Fund, L.P.
	 
	 	 	 	 	 	 
	 	 	By: AIG Horizon SBS GP, L.P.,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 	 	By: AIG Horizon Partners, LLC,
	 	 	Its General Partner
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ David Pinkerton
	 	 	Name:	 	David Pinkerton
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	175 Water Street, 26th Floor
	 	 	New York, New York 10038
	 	 	Attn: Astrid S. Tuminez
	 	 	Telephone No.:	 	212-458-2318
	 	 	Facsimile No.:	 	212-458-2250
	 	 	E-mail Address:	 	 

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 04/28/03	 	Cosmos Bio Life Sciences, LLC
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Robert G. Kalik
	 	 	Name:	 	Robert G. Kalik
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	5247 Wisconsin Avenue, N.W., No. 5
	 	 	Washington, DC 20015
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	202-537-2290
	 	 	Facsimile No.:	 	202-537-2291
	 	 	E-mail Address:	 	rkalik@kaliklewin.com

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 04/29/03	 	Eiichi Ida
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Eiichi Ida
	 	 	Name:	 	Eiichi Ida
	 

	 	Title:	 	 	 	 
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	4-9-6 Minami
	 	 	Azabu, Minato-ku Tokyo
	 	 	106-0047 Japan
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	81-3-3444-3905
	 	 	Facsimile No.:	 	81-3-3442-1570
	 	 	E-mail Address:	 	e-ida@ida-bldg.co.jp

 

 

PURCHASER SIGNATURE PAGE

     By his, her or its execution and delivery of this signature page, the undersigned Purchaser
hereby joins in and agrees to be bound by the terms and conditions of the:

     (i) Series C Preferred Stock Purchase Agreement dated as of December ___, 2002 (the
“Purchase Agreement”) by and among Iomai Corporation (the “Company”) and the
Purchasers listed on Exhibit A thereto, as to the number of shares of Series C Preferred
Stock of the Company set forth on Exhibit A thereto opposite the undersigned’s name, as a
“Purchaser” thereunder;

     (ii) Investor Rights Agreement dated as of December ___, 2002 by and among the Company and the
Purchasers listed on Exhibit A thereto (the “Investor Rights Agreement”), as a
“Purchaser” thereunder; and

     (iii) Stockholders’ Agreement dated as of December ___, 2002 by and among the Company, the
stockholders listed on Exhibit A thereto and the Purchasers listed on Exhibit B
thereto (the “Stockholders’ Agreement”), as a “Purchaser” thereunder; and

authorizes this signature page to be attached to the Purchase Agreement, the Investor Rights
Agreement and the Stockholders’ Agreement, or counterparts thereof.

	 	 	 	 	 	 	 
	Date: 06/03/03	 	Global Capital Finance Bekiligungun AG
	 
	 	 	 	 	 	 
	 	 	By:	 	/s/ Paul R. Hofer
	 	 	Name:	 	Paul R. Hofer
	 	 	Title:	 	Managing Director
	 
	 	 	 	 	 	 
	 	 	Record Address:
	 
	 	 	 	 	 	 
	 	 	Europa-Strasse 37
	 	 	8152 Glattbrugg
	 
	 	 	 	 	 	 
	 	 	Telephone No.:	 	+41 1 808 6016
	 	 	Facsimile No.:	 	+41 1 808 6019
	 	 	E-mail Address:	 	uschwerzmann@globalcapitalfinance.com

 

 

EXHIBIT A

SCHEDULE OF PURCHASERS

	 	 	 	 	 	 	 	 	 
	 	 	Shares of	 	 	Shares of	 
	Name
and Address
	 	Series B Preferred	 	 	Series C Preferred	 
	Elan International Services, Ltd.
	 	 	14,734,578	 	 	 	 	 
	Alexandria Real Estate Equities, L.P.
	 	 	 	 	 	 	565,483	 
	CNF Investments, LLC
Domain Partners V, L.P.
	 	 	 	 	 	 	22,097,320	 
	DP V Associates, L.P.
	 	 	 	 	 	 	521,998	 
	Essex Woodlands Health Ventures V, L.P.
	 	 	 	 	 	 	11,309,658	 
	FBR Infinity II Ventures (Israel) LP
	 	 	 	 	 	 	980,459	 
	FBR Infinity II Ventures LP
	 	 	 	 	 	 	894,318	 
	FBR Infinity II Ventures (Erisa) LP
	 	 	 	 	 	 	387,154	 
	Global Capital Finance GmbH & Co. Europe KG
	 	 	 	 	 	 	226,133	 
	MedImmune Ventures, Inc.
	 	 	 	 	 	 	11,309,658	 
	New Enterprise Associates 10, Limited
Partnership
	 	 	 	 	 	 	33,869,034	 
	NEA Ventures 2002, Limited Partnership
	 	 	 	 	 	 	59,941	 
	ProQuest Investments II, L.P.
	 	 	 	 	 	 	11,043,881	 
	ProQuest Investments II Advisors Fund, L.P.
	 	 	 	 	 	 	265,777	 
	SAM Sustainability Private Equity, L.P.
	 	 	 	 	 	 	4,523,863	 
	Technology Partners Fund VI, L.P.
	 	 	 	 	 	 	3,800,045	 
	Technology Partners Fund VII, L.P.
	 	 	 	 	 	 	9,228,681	 
	Technology Partners Affiliates VII, L.P.
	 	 	 	 	 	 	542,864	 
	 
	 	 	 	 	 	 	 	 
	Additional
Purchasers
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	China Development Industrial Bank Inc.
	 	 	 	 	 	 	4,523,863	 
	ETP/FBR Venture Capital II, LLC
	 	 	 	 	 	 	1,130,966	 
	Pan-Pacific Venture Capital Co. Ltd.
	 	 	 	 	 	 	2,261,932	 
	AIG Private Equity Portfolio, L.P.
	 	 	 	 	 	 	565,483	 
	AIG Private Equity Portfolio II, L.P.
	 	 	 	 	 	 	565,483	 
	AIG Horizon Partners Fund, L.P.
	 	 	 	 	 	 	1,900,022	 
	AIG Horizon Side-by-Side Fund, L.P.
	 	 	 	 	 	 	1,492,875	 
	Cosmos Bio Life Sciences, LLC
	 	 	 	 	 	 	67,858	 
	Eiichi Ida
	 	 	 	 	 	 	158,335	 

Pursuant to a Stock Purchase Warrant for 250,000 shares of Series C Preferred (the “FBR Series C
Shares”), Friedman Billings Ramsey & Co. is entitled to the registration rights of a Purchaser (not
an Other Holder) set forth in this Agreement with respect to the shares of Common Stock issuable
upon conversion of the FBR Series C Shares.

 

 

EXHIBIT B

SCHEDULE OF OTHER HOLDERS

	 	 	 
	 	 	Number and type of securities with
	Name	 	registration rights
	Maryland Health Care Product Development Corporation

	 	380,000 shares of Common Stock
	 
	 	 
	CZ Venture Operations, Inc.

	 	571,429 shares of Common Stock
	 
	 	 
	Eiichi Ida

	 	95,891 shares of Common Stock
	 
	 	 
	Yuichi Suzuki

	 	82,193 shares of Common Stock
	 
	 	 
	Toshirb Osoegawa

	 	95,891 shares of Common Stock
	 
	 	 
	MdBio, Inc., as trustee for and on behalf
of the Walter Reed Army Institute of Research

	 	650,000 shares of Common Stock

 

 

Table Of Contents

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	TABLE OF CONTENTS

	 
	 	 	 	 	 	 
	SECTION 1	 	 	 	 
	CERTAIN DEFINITIONS	 	 	1	 
	1.1
	 	Definitions	 	 	1	 
	 
	 	 	 	 	 	 
	SECTION 2	 	 	 	 
	REGISTRATION RIGHTS	 	 	6	 
	2.1
	 	Required Registrations.	 	 	6	 
	2.2
	 	Incidental Registration.	 	 	9	 
	2.3
	 	Aggregation	 	 	10	 
	2.4
	 	Registration Procedures.	 	 	10	 
	2.5
	 	Allocation of Expenses	 	 	13	 
	2.6
	 	Indemnification and Contribution.	 	 	13	 
	2.7
	 	Other Matters with Respect to Underwritten Offerings	 	 	16	 
	2.8
	 	Information by Holder	 	 	16	 
	2.9
	 	Market “Stand-Off’ Agreement	 	 	16	 
	2.10
	 	Limitations on Subsequent Registration Rights	 	 	17	 
	2.11
	 	Rule 144 Requirements	 	 	17	 
	2.12
	 	Termination	 	 	17	 
	 
	 	 	 	 	 	 
	SECTION 3	 	 	 	 
	PARTICIPATION RIGHTS	 	 	18	 
	3.1
	 	Participation Rights.	 	 	18	 
	3.2
	 	Termination	 	 	20	 
	 
	 	 	 	 	 	 
	SECTION 4	 	 	 	 
	COVENANTS OF THE COMPANY	 	 	20	 
	4.1
	 	Affirmative Covenants	 	 	20	 
	4.2
	 	Financial Statements and Other Information	 	 	23	 
	4.3
	 	Negative Covenants of the Company	 	 	24	 
	4.4
	 	Termination of Covenants	 	 	25	 
	 
	 	 	 	 	 	 
	SECTION 5	 	 	 	 
	TRANSFERS OF RIGHTS	 	 	26	 
	5.1
	 	Transfers of Rights under this Agreement	 	 	26	 
	 
	 	 	 	 	 	 
	SECTION 6	 	 	 	 
	MISCELLANEOUS	 	 	26	 
	6.1
	 	Notices	 	 	26	 
	6.2
	 	Successors and Assigns	 	 	27	 
	6.3
	 	Entire Agreement	 	 	27	 
	6.4
	 	Amendments and Waivers	 	 	27	 

62

 

Table Of Contents

(continued)

	 	 	 	 	 	 	 
	 	 	 	 	Page	 
	 	 	 	 	 	 
	6.5
	 	Counterparts	 	 	27	 
	6.6
	 	Severabilitv	 	 	27	 
	6.7
	 	Specific Performance	 	 	27	 
	6.8
	 	Governing Law; Jurisdiction; Waiver of Jury Trial	 	 	28	 
	6.9
	 	Titles and Subtitles	 	 	28	 
	6.10
	 	Confidentiality	 	 	28	 
	6.11
	 	Additional Purchasers	 	 	28	 
	6.12
	 	Section Heading and References	 	 	28	 
	6.13
	 	Further Assurances	 	 	28	 
	6.14
	 	Omissions; Cumulative Rights	 	 	29	 

63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]